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Abstract  
 
Introduction: Breast cancer is frequently diagnosed in women in both developed and 
developing countries and poses a major health problem throughout the world. The current 
standard treatment for breast cancer patients is radiation, surgery and chemotherapy or a 
combination of surgery with chemotherapy. The unresponsiveness of cancer cells to 
chemotherapeutics, however, is still a main concern. During chemotherapeutic treatment with 
Doxorubicin, normal and healthy neighbouring cells are also damaged. Apoptotic or senescent 
fibroblasts in the tumour microenvironment can then secrete a variety of bioactive molecules 
which promote tumour growth, metastasis and drug resistance.  
 
Methods: Mouse embryonic fibroblasts (MEFs) were cultured and treated with Doxorubicin 
to induce apoptosis and senescence respectively. An SA-ß-gal stain was used to determine 
the number of senescent cells in the cell population and expression of apoptotic and senescent 
markers were determined through western blotting. Conditioned media was collected from the 
MEFs after apoptosis and senescence induction and used to assess the paracrine effects 
between fibroblasts and E0771 cells. 
 
Results and discussion: Doxorubicin (1 µM) was able to significantly induce 
apoptosis in MEFs after 24 hours. During senescence induction, 2 µM of Doxorubicin 
treatment for 4 hours was unable to induce 80% of senescence in the MEF population. The 
western blot analyses show that the expression of many apoptosis and senescence markers 
significantly increased or decreased after Doxorubicin treatment. Furthermore, the results 
indicate that senescent fibroblasts (56%) were able to significantly increase cell viability in 
E0771 cells following treatment with Doxorubicin.  
 
Conclusion: Our results highlight the fact that the tumour microenvironment is extremely 
complex and how important it is that chemotherapeutic agents such as Doxorubicin should 
specifically target cancer cells. Once healthy, neighbouring stromal cells such as fibroblasts 
are affected by chemotherapeutic agents, they have the ability to secrete paracrine factors 
that enhance breast cancer growth and induce therapeutic resistance by evading cell death.  
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Chapter 1: Literature Review 
 
1.1 Breast cancer: Introduction  
 
Breast cancer frequently occurs in women in both developed and developing countries and 
therefore creates a major financial and health burden throughout the world (Desantis et al., 
2016). The heaviest global burden is experienced in developed countries, but the incidence in 
developing countries are rapidly increasing. Although many factors contribute to the 
prevalence, risk and distribution of cancer, many are associated with socioeconomic 
development (Caldwell, 2001; Bray et al., 2018). With the rapidly growing populations, one in 
ten newly diagnosed cancers each year, will be breast cancer (Siegel et al., 2018).  
 
Worldwide, one out of four women will be diagnosed with breast cancer during their lifetime 
(Bray et al., 2018). Out of 36 different types of cancers worldwide, lung cancer is the leading 
cause of death among women, followed by breast cancer (Torre et al., 2017; Bray et al., 2018). 
However, breast cancer is the most frequently diagnosed cancer in most countries worldwide 
(154 countries out of 185). Assuredly, the use of chemotherapy has decreased the death rate 
specifically for breast cancer by 25%, since 1990 (Parton et al.,  2001). However, over the last 
three decades, global breast cancer incidence has increased annually by 3.1% and during 
2010, 1.6 million cases of breast cancer were reported (Forouzanfar et al., 2011; Looi et al., 
2013). Shockingly, the most recent data indicates that approximately 2.1 million breast cancer 
cases were reported during 2018 and 600 000 cases resulted in death (Bray et al., 2018). In 
South Africa, 22% of the female population was diagnosed with breast cancer during 2013 
and considering that South Africa is categorized as a developing country, breast cancer 
incidence is alarmingly high and continues to increase annually since 2008 (NCR, 2013).  
 
Different gene mutations can result in the onset of different subtypes of breast cancer which 
makes it more difficult to determine the exact diagnosis as well as treatment options that will 
be most successful to eliminate the cancer (Sims, 2007). Breast cancer can be categorized in 
many ways, including tumour marker expression, clinical features and its histological type (Li, 
Uribe & Daling 2005; Gudavicience et al., 2005) . The breast mainly consists of  lobular (also 
sometimes referred to as glandular) tissue, ductal cells  and stromal tissues (Sharma et al., 
2010). Lobular tissue contains milk producing glands, ductal cells form small tubes that are 
responsible for transporting milk towards the nipple and stromal tissues are constituted of fatty 
and fibrous connective tissues. Different types of tumours can therefore develop in different 
areas of the breast. To further contribute to the complexity of cancer, breast cancer can also 
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be characterized as non-invasive or invasive (Pareja et al., 2016). In non-invasive breast 
cancer, the cancerous cells are unable to invade surrounding connective tissues within the 
breast because they are confined within the breast milk ducts. The form of non-invasive breast 
cancer that occurs the most is ductal carcinoma in situ which indicates that the cells that line 
the milk ducts have become cancerous. Invasive breast cancer occurs once the cells break 
through the lobular wall (milk producing glands) and invades the surrounding fatty and 
connective tissue in the breast. Lobular carcinoma in situ (LCIS) is invasive and is 
characterized by a significant increase in the number of cells within the milk glands. LCIS is 
also the type of breast cancer that occurs most frequently. The incident rates of lobular 
carcinomas in the United States are increasing at an alarming rate when compared to ductal 
carcinomas (Li et al., 2003). The percentage of lobular carcinoma has increased by 65% from 
1987 to 1999, while ductal carcinoma has only increased by 3% (Arpino et al., 2004). 
 
Immunohistochemical subtyping for estrogen receptor (ER), human epidermal growth factor 
receptor-2 (HER2) and progesterone receptor (PR) further divides breast cancer into 4 
molecular subtypes: Luminal A (ER and/or PR positive and HER2 negative), Luminal B (ER 
and/or PR positive and HER2 positive or negative), Triple negative breast cancer (TNBC) 
(Hormone receptor negative) and HER2 overexpression (Hormone receptor negative and 
HER2 positive) (Wang, 2017). TNBC is considered to be an aggressive form of breast cancer 
because the cancer often returns after a few years and presents in 10% to 20% of breast 
cancer cases (Kumar & Aggarwal, 2008; Pareja et al., 2016). It does not respond to hormonal 
therapy treatments because the cells confined within the tumour are negative for 
progesterone, estrogen and HER2 receptors. In 2009 it was reported that 500 000 women die 
every year because of breast cancer and 150 000 (30%) of these cases are diagnosed with 
TNBC (Kumar & Aggarwal, 2008).  
 
Several studies have focused on and examined the clinical and pathological differences 
between ductal and lobular carcinomas, while less attention is given to rarer types of breast 
cancer which account for 10% of all cases (Li et al., 2005; Gudaviciene et al., 2015). These 
types of breast cancer include:  
• Mucinous carcinoma of the breast: This carcinoma contains increased amounts of 
extracellular mucus that is in direct contact with the stroma. Most of the tumour mass 
is constituted of acellular mucus and not neoplastic cells.  
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• Medullary carcinoma: This carcinoma forms a spherical tumour mass and is 
constituted of lymphocytes and poorly differentiated epithelial cells.  
• Metaplastic carcinoma: The carcinoma is constituted of cells that are normally not 
found within the breast.  
• Inflammatory breast cancer: It is a rapidly growing form of breast carcinoma associated 
with thickening and reddening of the skin over 50% of the breast and is not always 
associated with tumour development.  
• Metastatic cancer: The cancer cells have spread beyond the breast tissue and often 
infiltrate into brain, lungs and bone tissue.  
 
It is therefore important to evaluate all the characteristic differences between carcinoma types 
to be able to understand the nature of the tumour, etiologies and clinical features of different 
types of breast cancers (Li et al., 2005).   
 
The risk factors for breast cancer often include: previous cancer history, family history of 
cancer, hormonal changes as well as dietary and lifestyle factors (Cauchi et al., 2016). The 
most common symptom for breast cancer is a lump in the breast or armpit region. In advanced 
or metastatic stages, bone pain, shortness of breath, loss of appetite and weight loss can 
occur. A lobule biopsy is most commonly used to diagnose breast cancer (Li et al., 2005).  
 
Breast cancer accounts for 25% of all cancer cases worldwide and is not limited to females; 
approximately 1% of breast carcinomas occur in the male population (Giordano et al., 2004; 
Torre et al., 2012). Survival rates vary, but increased survival rates are expected to occur each 
year which can be attributed to various breakthroughs that have been made in early diagnosis 
of breast cancer, screening methods and the development of new treatment strategies 
(Nounou et al., 2015). 
 
1.2 Treatment strategies for breast cancer  
 
Although the current standard treatment for breast cancer patients is radiation, surgery and 
chemotherapy or a combination of surgery with chemotherapy, the therapeutic options for 
breast cancer treatment depends on the biological characteristics of the tumour (Amornsupak, 
et al., 2014). Hormone therapy is often recommended for a low-grade, ER positive tumour 
whereas chemotherapy is administered depending on the hormonal status of the tumour and 
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is generally only administered to high grade tumours (Lovitt, Shelper & Avery, 2018). Early 
diagnosis of breast cancer generally increases the chance of survival, but the 
unresponsiveness of cancer cells to chemotherapeutics is still a major concern where the 
response rate to chemotherapeutics is estimated to be only 50% (Rampurwala, Rocque & 
Burkard, 2014). In addition, it has been reported that about 30% of early stage breast cancer 
patients are at risk for the development of drug resistance and cancer recurrence (Chang, 
2012). Triple negative breast cancer (TNBC) is the most diagnosed type of breast cancer and 
therefore has the highest mortality rate (Aydinlik et al., 2017). Treatment failure generally 
occurs when cancer cells become resistant to chemotherapeutic agents, which leads to 
relapse, metastasis and ultimately death, despite the continuous administration of anti-cancer 
drugs (Housman et al., 2014).  
 
During the 1960’s, Doxorubicin (DXR) was introduced as an anti-cancer therapy (a 
chemotherapeutic) and is currently one of the most potent broad-spectrum anti-tumour 
antibiotics commonly used to treat breast, lung and ovarian cancer (Fujita et al., 2011; Osman 
et al., 2013). DXR (also known as Adriamycin) belongs to the anthracycline family and was 
first isolated from a soil bacterium, Streptomyces peucetius (Yang & Teves, 2015). DXR 
contains both p-quinone and p-hydroquinine structures which allows for the production of free 
radicals through cytochrome P450 mediated reduction and iron-mediated oxidation of DXR. 
NADPH allows DXR to undergo a one-electron reduction of the p-quinone to form a 
semiquinone radical to produce free hydroxyl radicals, which is responsible for DNA damage 
(Mizutani et al., 2003).  
 
DXR is commonly used to treat breast, bladder, lung and ovarian cancer, as well as soft tissue 
sarcoma, Hodgkin’s lymphoma and Kaposi’s sarcoma (Momparler et al., 1976; Rivankar, 
2014). Many studies have indicated that DXR shows great efficacy in the killing of cancer cells, 
in solid tumours as well as in blood cancers like leukemia (Yang & Teves, 2015), however, 
drug resistance and possible side effects including heart muscle damage limits the success of 
the treatment (Thorn, 2011).  
 
Various mechanisms for DXR-mediated cell death have been proposed, including (1) 
topoisomerase II poisoning, (2) oxidative stress and (3) the formation of DNA adducts (Yang 
et al., 2014). However, some mechanisms such as DNA and RNA synthesis inhibition can 
only be identified at dosages higher than the clinical dose (~ 40 to 60 mg/m²) (Gewirtz, 1999). 
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Anthracyclines are classified as planar molecules which are able to intercalate between 
neighbouring DNA base pairs. Once DNA is topologically constricted, the double helix unwinds 
and produces DNA supercoils, which severely increases torsional stress (Yang et al., 2014).  
 
1.2.1 Topoisomerase II poisoning  
 
Topoisomerases are evolutionary conserved from bacteria to humans and are used to 
facilitate DNA transcription, regulation and synthesis. Topoisomerase II binds DNA supercoils 
and breaks the strands of one DNA duplex, while the other DNA strand is passed through the 
forming gap and reseals the break. A deficiency in topoisomerase II prevents cytokinesis and 
ultimately results in cell death (Carpenter et al., 2004). Anti-cancer drugs like DXR specifically 
target topoisomerases to kill tumour cells. DXR poisons topoisomerase II by diffusing into the 
nucleus where it intercalates with DNA.  
 
1.2.2 Oxidative stress  
 
The addition of one electron to the quinone structure of DXR can readily form a semiquinone 
radical, which is able to react with oxygen and produce reactive oxygen species (ROS) (Myers, 
1998). Once the reaction is completed, superoxide and hydrogen molecules are generated, 
leading to severe DNA damage. The sudden increase in ROS can also stimulate the onset of 
lipid peroxidation (the oxidative degradation of lipids) as well as the induction of oxidative 
stress. Furthermore, DXR is also an iron chelator and can convert hydrogen peroxide into 
highly reactive hydroxyl radicals (Myers et al., 1998). The release of DXR induced free radicals 
can thus potentially cause oxidative damage which will result in DNA damage and cell death. 
It was indicated in a study that slow intravenous infusion of DXR (0.1 µM) into the plasma after 
72 to 96 hours resulted in a 4-fold increase of DNA base oxidation in breast cancer patients 
(Doroshow et al., 2001). 
 
1.2.3 DNA adduct formation 
  
The target site for DXR intercalation in DNA is adjacent to guanine-cytosine base pairs 
(Livraghi & Garber, 2015). The formation of DNA adducts activates the DNA damage response 
and leads to cell death, independently of topoisomerase II. The formation of DNA adducts 
after DXR intercalation is identified at clinically applicable drug concentrations, which suggests 
that DXR-DNA adducts are formed during chemotherapeutic treatment (Taatjies et al., 1997).  
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The mechanism of action of DXR and many anthracycline drugs have been intensively 
studied, but the exact mechanisms for cell death remain controversial (Yang et al., 2014). 
Therefore, by understanding the mechanism of DXR-mediated cell death, future treatment 
strategies can be developed to enhance cell death of cancer cells and to minimise side effects 
induced by chemotherapeutic treatments.  
 
1.3 Development of treatment resistance 
 
In general, treatment failure can be contributed to chemotherapeutic resistance in more than 
90% of patients with metastatic cancer and failure following DXR treatment is also subjected 
to these statistics. Once the cells are exposed to DXR, the stress responsive Y-box binding 
protein 1 (YB-1) translocates to the nucleus to induce the expression of the multidrug 
resistance gene 1 (MDR1) (Chen & Simon, 2000). The MDR1 gene encodes the P-
Glycoprotein to export substances to the outside of the cell to protect cells from toxic 
substances (Dresher, 2002). High levels of MDR1 could therefore limit the ability of DXR to 
infiltrate into cancer cells, which promotes DXR resistance and increased cell growth (Yang et 
al., 2010). Similarly, Shen et al demonstrated that MDR1-transduced human MDA-MB-435 
(MDR) breast cancer cells are 9-fold more resistant to DXR than wild type MDA-MB-435 cells. 
DXR uptake in the nucleus of MDR cells was 2-fold lower when compared to the wild type 
cells (Shen et al., 2008).  
 
Exposure to DXR induces severe DNA damage which can induce point mutations and single 
and double strand breaks (Weil and Chen, 2012). Cells are able to employ various DNA repair 
mechanisms, including base extension repair (BER), homologous recombination (HR) and 
mismatch repair to restore damages on a regular basis (Sirbu et al., 2013). The ability of 
injured cells to induce DNA repair for survival is optimal for normal cells, but this repair process 
also allows tumour cells to undergo repair after chemotherapy or radiation. 
 
Novel anti-cancer therapies include agents that target specific molecular defects in cancer 
cells to increase treatment efficacy and reduce toxicity (Livraghi & Garber, 2015). Poly (ADP-
ribose) polymerases (PARPs) respond to DNA damage caused by DXR where PARP- 1, -2 
and -3 are classified as DNA damage-dependent PARPs. PARP proteins have enzymatic and 
scaffolding properties that can recruit DNA repair proteins and PARP 1 and 2 is responsible 
for BER functioning, to repair single strand DNA breaks (Weil and Chen, 2012). The inhibition 
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of BER can therefore eventually lead to cell death. PARP activation is driven by DNA damage 
and is involved in post-transcriptional modification of nuclear proteins (Livraghi & Garber, 
2015). In human cells, PARP-1 recruitment and activation is the first response to DNA damage 
caused by DXR (Mortusewicz et al., 2007).  
 
Furthermore, Guo et al suggested that there are four possible fates for DXR once it enters 
MCF-7 breast cancer cells (Guo et al., 2016):  
1. Cytoplasmic aldo-keto reductases metabolize DXR into a smaller toxic metabolite (13-OH-
doxorubicinol). 
2. It is taken up and isolated in lysosomes. 
3. It binds to mitochondrial DNA before reaching the nucleus and induces oxidative stress in 
mitochondria, where after severely damaged and dysfunctional mitochondria are marked 
for degradation through the process of mitophagy. 
4. Higher dosages of DXR are removed from the cancer cells via drug transporters. 
 
These mechanisms could potentially explain why only small amounts of DXR is found in the 
nucleus of cancer cells (Guo et al., 2016).  
 
Phosphoinositide 3-kinase (PI3K) dependent phosphorylation of downstream effector and 
transducer proteins is an important signalling pathway to determine cell fate after exposure to 
DNA damaging agents, like DXR (Harper & Elledge, 2007). The DNA damage response is a 
signalling cascade that mediates the response to cellular damage by inducing DNA repair, cell 
cycle arrest and, if necessary, activating apoptosis. As mentioned previously, DNA damage 
causes DNA strands to break, which inactivates pathways mediated by PI3K related protein 
kinases (Cruet-Hennequart et al., 2012).  
 
1.4 The Phosphoinositide 3-kinase pathway in cancer  
 
The phosphoinositide 3-kinases (PI3Ks) are defined as a group of lipid kinases that 
biochemically phosphorylate the 3-hydroxyl group of phosphoinositides (Cantley, 2002). Class 
IA PI3Ks are heterodimers made up of a catalytic subunit (p110) and a regulatory subunit 
(p85) and is often deregulated in cancer (Baselga, 2011). The PI3K pathway is activated once 
ligands or growth factors bind the receptor tyrosine kinase (RTK) on the cell surface. Once the 
receptors are activated, phosphatidylinositol bisphosphate (PIP₂) is phosphorylated to 
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phosphatidylinositol triphosphate (PIP₃) (Maehama & Dixon, 1998). PIP₃ acts as a binding site 
for Akt (a serine/threonine kinase) which is then phosphorylated at the cell membrane on 
Serine473 (Ser473) by mammalian target of Rapamycin complex 2 (mTORC2) and on 
Threonine308 (Thr308) by Pyruvate dehydrogenase kinase isoform 2 (PDK2) to stimulate cell 
growth and protein synthesis (Liu et al., 2009) (Figure 1.1). Akt is therefore involved in many 
downstream pathways that regulate cellular metabolism and proliferation and protects the 
cells from apoptosis (Kumar et al., 2013). However, hyperactivation of Akt often occurs in 
many cancers, which include breast (Chua et al., 2009) and prostate (Ayala et al., 2004) 
cancer, where it has been shown in tumour samples collected from breast and prostate cancer 
as well as leukaemia patients that mutations in the Akt signalling pathway is a regular 
occurrence (Sadeghi, 2012). Phosphate mediated Akt signalling is negatively regulated 
through the phosphatase activity of Phosphatase and tensin homolog (PTEN) that acts as a 
tumour suppressor (Waite et al., 2002; Xu et al., 2014). Once phosphatase activity is lost, PIP₃ 
is not dephosphorylated to PIP₂, allowing the phosphate molecule to be transported to Akt. 
This transfer then induces the expression of MDM2, BAD, mTOR and p21 to inhibit apoptosis 
activation, activate cell cycle progression and promote tumour growth by impairing cell cycle 
arrest at the G1 and G2 phases (Madrid et al., 2000; Kandel et al., 2002).  The PI3K pathway 
therefore plays a major role in many cellular functions such as cell proliferation, cellular 
metabolism, differentiation and cell survival (Baselga, 2011). 
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Figure 1.1: The PI3K/Akt signalling pathway and its downstream targets (from Sawyers & Vivanco, 
2002).  
 
Genetic mutations in the PI3K pathway occur in 25% of breast cancer where most mutations 
occur in the PI3KCA gene, which encodes the p110α subunit and allows amino acids to be 
substituted in the kinase domain (exon 20) as well as the helical domain (exon 9) (Stemke-
Hale et al., 2008; Baselga, 2011). Once the mutations occur, enzymatic functions are 
significantly increased which enhances the effects of downstream signalling components (like 
Akt) to promote oncogenic transformation (Figure 1.2) (Baselga, 2011). 
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Figure 1.2: The PI3K/Akt/mTOR and the RAS/RAF/MEK/MAPK pathways frequently harbour 
oncogenic transformations in cancer (adapted from Toss and Cristofanilli, 2015). 
 
The ability of PI3K to induce pro survival signalling is therefore linked with the activation of Akt 
but can also be dependent on Ras activation, which is part of the GTPases family. 
Approximately 25% of human tumours have mutations in a member of this family (Castellano 
& Downward, 2011).  
 
1.4.1 Ras/Raf/MEK/ERK signalling contributes to pro-survival signalling of 
cancer cells 
 
The Ras-Raf-MEK-ERK pathway (MAPK/ERK pathway) is constituted of proteins that are 
located within the cell and functions to transport signals from the surface receptor to the cell’s 
DNA to regulate gene expression (McCubrey et al., 2007). Ras is a GTP-binding protein and 
is generally the upstream molecule of many signalling pathways, including PI3K/Akt and 
Raf/MEK/ERK (Figure 1.2) (McCubrey et al., 2012). Once Ras is activated, the receptor 
tyrosine kinase effector, Raf (named for Rapidly Accelerated Fibrosarcoma), is recruited and 
phosphorylated at the cell membrane to stimulate serine-threonine kinase activity (Leicht et 
al., 2007). Activated Raf induces the activation and phosphorylation of Mitogen-activated 
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protein kinase (MEK1/MEK2) and extracellular signal–regulated kinases (ERK1/2) (Robinson 
& Cobb, 1997; Yoon & Seger, 2006). Extracellular signal related-kinases are Serine/Threonine 
kinases and their activities are positively regulated by phosphorylation mediated by MEK. ERK 
then translocates to the nucleus to regulate transcription factors involved in cell proliferation 
and survival, which is mostly associated with ERK2 (Montagut & Settleman, 2009). Once this 
pathway becomes dysregulated during cancer development, cellular growth arrest is inhibited, 
which will allow the cancer cells to rapidly proliferate (Hanahan & Weinberg, 2000; Shields et 
al., 2000) (Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: The Raf/MEK/ERK signalling pathway (adapted from Park, 2014). 
 
The Raf/MEK/ERK pathway regulates many processes in cells such as apoptosis, 
differentiation and cell cycle progression. It inhibits the phosphorylation and inactivation of 
many apoptotic molecules including Bim, caspase 9, Bcl-2 and Bad (Steelman et al., 2004). It 
is therefore possible that cross-talk occurs between the PI3K/Akt and Raf/MEK/ERK pathways 
to ultimately prevent apoptosis from occurring.  
 
Mutations at membrane receptors (Ras, PI3K, Akt) often cause this signalling pathway to 
become abnormally activated and occurs in approximately 20% of human neoplasms 
(Montagut & Settleman, 2009). It is also suggested in many studies that the Raf/MEK/ERK 
pathway contributes to chemotherapeutic drug resistance in cancer cells. Abnormal activation 
of Raf induced resistance to both DXR and paclitaxel in breast cancer cells (Garnett et al., 
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2004). Furthermore, Ras also has the ability to increase the expression of several molecules 
that are involved in cell cycle regulation including p53, p21 and p16. Ras therefore induces a 
permanent cell cycle arrest at the G1 phase, which is associated with a significant increase in 
the expression of the above-mentioned proteins (Serrano et al., 1997).  
 
Ras proteins are considered to be molecular switches for various signalling pathways that 
regulate cell behaviour including cell proliferation and cell death (Shields et al., 2000). Tumour 
development and growth is highly dependent on the continued activation of Ras to avoid 
apoptosis, which is generally mediated by the activation of NFκB. However, some studies 
suggest that Ras induces pro- and anti-apoptotic signalling, depending on the cell type 
(Kaltschmidt et al., 2000; Ryan et al., 2000).  
 
1.5 Cell death: Apoptosis in cancer  
 
Apoptosis is a form of cell death that occurs during growth and development to maintain 
physiological homeostasis, with the ability to extensively delete cells with little tissue disruption 
and avoids the onset of inflammation (Kerr et al., 1972; Elmore, 2007). Uncontrolled tumour 
growth generally occurs when proliferation is enhanced and apoptosis is limited (Parton et al., 
2001). Indeed, the biology or functioning of individual tumours can be described by examining 
the control and regulation of apoptosis at a molecular and biochemical level. Once these 
mechanisms are understood, individual tailored treatments can be developed to maximise the 
efficacy of treatment. A major method for apoptosis in situ detection and quantification is 
morphological assessment with either light or electron microscopy (Kerr et al., 1972; Doonan, 
2008). Key features of apoptotic cells include cell shrinking, membrane blebbing and DNA 
fragmentation (Kerr et al., 1972; Elmore, 2007).  
 
Carcinogenesis in epithelial tissue is characterized by defects in cellular functions, the 
accumulation of genetic mutations and rapid growth of cancer cells (Parton et al., 2001). It is 
believed that these processes can occur sometimes up to 30 years before the clinical onset 
of breast cancer (Kelloff et al., 2000). During premalignant stages, various biomarkers of the 
cell cycle are severely altered, specifically markers for proliferation and apoptosis. As soon as 
24 hours after the onset of chemotherapy treatment, apoptosis is greatly increased in breast 
tumours and is commonly associated with reduced cell proliferation. Once the chemotherapy 
phase is completed, proliferation is reduced and Bcl-2 (an anti-apoptotic protein expressed in 
80% of breast cancers) levels are decreased (Ellis et al., 1997). 
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Extensive studies of the Bcl-2 family as well as p53, the tumour suppressor gene, has been 
done in breast cancer to describe its involvement in the apoptotic process (Parton et al., 2001). 
The activation of p53 can induce apoptosis and is considered to be one of the key mechanisms 
of action during DXR therapy. The Bcl-2 family include the molecules Bax, Bak and Bad, while 
Bcl-2, Bcl-xl and Mcl-1 are anti-apoptotic proteins (Parton et al., 2001). The principal 
executioners of cell death during apoptosis are proteolytic enzymes known as caspases, 
where eleven caspases have been associated with humans thus far (Parton et al., 2001). 
Caspases are inactive zymogens during synthesis and is activated through cleavage via an 
intracellular proteolytic cascade, providing them with the ability to induce apoptosis. Higher 
levels of apoptosis have been associated with increased cleavage of caspases 3, 6 and 8 
(Shalini et al., 2015). Inhibitors of apoptosis (XIAP, NIAP cIAP1, cIAP2, and survivin) prevents 
the apoptotic pathway from continuing to the next phase by inhibiting the function of caspases, 
through direct binding to them (Hersey et al., 2003; Rathore et al., 2017). Apoptotic inhibitors 
can therefore potentially be used as predictive or prognostic biomarkers associated with 
cancer development. However, cancer cells are becoming more resistant to apoptotic cell 
death and higher dosages of chemotherapeutics are required to kill defective and mutated 
cells, but can also induce cell death in healthy tissues, which produces severe and unwanted 
side effects (Rathore et al., 2017).   
 
1.5.1 The p53 signalling pathway in apoptosis  
 
The p53 pathway responds to extrinsic and intrinsic stress signals that alter cellular 
homeostatic mechanisms responsible for monitoring chromosome segregation, DNA 
replication and cell division (Vogelstein et al., 2000). Once a stress signal occurs, the p53 
protein is activated through post-translational modifications to induce cell cycle arrest (induces 
cellular growth arrest temporarily until damage is resolved) or apoptosis (Apella and Anderson, 
2001). The p53 pathway activates proteins that can alter the cellular environment in response 
to cellular stressors (Figure 1.4). p53 mutations are often the most common mutational events 
associated with cancers (Harris & Levine, 2005).  
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Figure 1.4: Different types of stress signals activate the p53 protein, which enhances the role of 
p53 as a tumour suppressor gene. DXR induces DNA damage in several cell types which can result 
in oncogene transformation. However, the activation of p53, a tumour suppressor protein, inhibits the 
function of E2F transcription factor 1 (E2F-1) resulting in cell cycle arrest (adapted from Harris and 
Levine, 2005). 
 
 
DNA alterations or mutations associated with cancer often occur during base alkylation, ultra-
violet (UV) or gamma irradiation and during the production of oxidative free radicals (Harris & 
Levine, 2005). Fortunately, the cell is able to employ a different detection and repair 
mechanism, for each above-mentioned damaging agent. Proteins that are responsible for the 
detection and repair of DNA damage has specific enzymatic activities that indicates to the p53 
protein that DNA damage has occurred (Broustas et al., 2014). The enzymatic activities induce 
post-translational modifications, which results in phosphorylation, methylation, acetylation or 
ubiquitination of the p53 protein (Harris & Levine, 2005).  Protein modifications modify the p53 
pathway in two ways (Harris & Levine, 2005). The first modification is the increase in the half-
life of the protein in the cell, which is usually between six and twenty minutes, but changes to 
hours and results in a 3 to 10-fold increase in p53 protein concentration within a cell. The 
second modification refers to the enhanced ability of p53 to promote transcription after binding 
to specific DNA sequences. 
 
The p53 protein responds to many stress signals  which can potentially disrupt cell duplication 
and lead to an increased cellular mutation rate or abnormality during cell division (Harris & 
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Levine, 2005). Therefore, p53 gene knockdown increases the susceptibility of an organism to 
develop cancer, even at a young age (Malkin et al., 1990). The limited ability of cells to divide 
once the cells are isolated from an organism and grown in culture is referred to as senescence. 
A senescent phenotype is therefore induced once cell division stops. Furthermore, p53 can 
also be activated from the mutational inactivation of certain tumour suppressor genes such as 
retinoblastoma (RB) (Sherr & McCormick, 2002). The RB protein is therefore often found in 
cells in a complex with p53 and is associated with enhanced p53 activity and increased 
apoptotic activity (Xiao et al., 1995).  
 
The p53 pathway therefore plays a dual role in preventing the onset of cancer in a cell 
population by firstly, inhibiting the cell cycle if the error rate is increased to prevent cancer cells 
from mutating and secondly by inducing apoptosis once mutations or severe damage occurs 
in the cell cycle.   
 
1.5.2 Apoptotic pathways 
 
As mentioned earlier, the p53 protein is part of two distinct apoptotic signalling pathways that 
result in the activation of caspases which mediate cell death (Vogelstein et al., 2000) (Figure 
1.5). The extrinsic pathway is constituted of certain death receptors that is part of the tumour 
necrosis factor receptor (TNF-R) family and by forming a death inducing signalling complex 
(DISC), caspases can be activated to induce apoptosis (Locksley et al., 2001). The intrinsic 
pathway is activated once DNA damage occurs and is associated with mitochondrial 
depolarization and cytochrome c release into the cytoplasm and together with apoptotic 
protease-activating factor-1 (Apaf-1) and procaspase 9, cytochrome c forms an apoptosome 
to promote caspase activation (Zha et al., 1996; Wang et al., 2009).  
 
1.5.2.1 The extrinsic apoptotic pathway  
 
The p53 protein activates the extrinsic pathway by inducing genes that encode 
transmembrane proteins (Locksley et al., 2001). The TNF-R family is made up of cysteine-rich 
extracellular domains, referred to as ‘death domains’. The death domain transmits the death 
signal at the cell surface receptor to the intracellular signalling pathway. The best identified 
ligands and death receptors include tumour necrosis factor (TNF)-α and tumour necrosis 
factor receptors-1 and -2 (TNFR1 and TNFR2); Fas ligand (FasL) and CD95/Fas receptor 
(FasR); TNF-related apoptosis inducing ligand (TRAIL) or Apo2Ligand (Apo2L) and death 
receptor-4 and -5 (DR4 and DR5) (Ashkenazi et al., 1998; Peter and Kramer, 1998; Suliman 
et al., 2001). Upon binding of their respective ligands, these death receptors trimerise and the 
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resultant clustering of the associated cytoplasmic death domains results in the acquisition of 
adaptor molecules such as Fas-associated protein with death domain (FADD) that has a death 
effector domain (DED). The DED of the adaptor protein attaches to the DED of the inactive 
initiator caspase 8, creating a complex called death inducing signalling complex (DISC) 
leading to the activation of an active initiator caspase. The activated initiator caspase in turn 
activates effector caspases (caspase 3/6/7) which leads to cleavage of substrates, ultimately 
inducing apoptosis (Kischkel et al., 1995).  
 
1.5.2.2 The intrinsic apoptotic pathway  
 
The intrinsic apoptotic signalling pathway has non-receptor mediated stimuli that produce 
intracellular signals (Elmore, 2007). These intracellular signals act directly on targets within a 
cell and is referred to as ‘mitochondrial-initiated’ events. Various damaging stimuli like toxins, 
hypoxia, free radicals and the absence of hormones and growth factors induce changes in the 
inner mitochondrial membrane, which results in an opening of the mitochondrial permeability 
transition pore (MPT) and loss of the mitochondrial transmembrane potential. Once 
mitochondria become depolarized, cytochrome c is released from the inner mitochondrial 
membrane into the cytosol. Cytochrome c then binds to and activates Apaf-1 and procaspase 
9 to form a heptameric protein complex termed the apoptosome (Chinnaiyan, 1999; Zha et al., 
1996; Hill et al., 2004). Apaf-1 contains Deoxyadenosine triphosphate (dATP) as a cofactor 
and when cytochrome C binds to Apaf-1, it induces hydrolysis of dATP to dADP, which is 
subsequently replaced by exogenous dATP. The active apoptosome recruits caspase 3, which 
is then activated by caspase 9 to induce cell death.  
 
Mitochondrial events during apoptosis is controlled and regulated by the Bcl-2 family of 
proteins (Cory & Adams, 2002). Bcl-2 proteins maintains mitochondrial membrane 
permeability and can be pro- or anti-apoptotic. Pro-apoptotic family members are responsible 
for releasing cytochrome c from the mitochondria through pore formation (Kuwabara et al., 
2002). Some cells do not die in response to the activation of the extrinsic pathway alone and 
requires another step where the intrinsic pathway is also activated. This step is induced by 
caspase 8 where it also targets the BH3-only protein Bid (BH3-interacting-domain death 
agonist) for cleavage to generate the activated fragment, t-Bid; t-Bid then directly activates 
proteins to induce mitochondrial outer membrane permeability (MOMP) to co-activate the 
intrinsic pathway (Li et al., 1998). Even though activation of these two apoptotic pathways is 
induced differently, the above mentioned suggests that cross-talk between the pathways 
facilitates the amplification of the extrinsic pathway via the intrinsic pathway, which is referred 
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to as the ‘mitochondrial amplification loop’, to ensure that cell death is induced (Fulda & 
Debatim, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: The intrinsic and extrinsic mitochondrial pathways of p53 induced apoptosis (adapted from 
Haupt et al., 2003). 
 
 
Apoptosis significantly contributes to the tumour response after chemotherapy to ultimately 
prevent the cancer cells from growing (Kim et al., 2006). However, the amount of cell death 
from apoptosis after a lethal dosage administration of anti-cancer drugs does not always 
correspond with the observed tumour response. Clonogenic assays indicate that non-
apoptotic forms of cell death occur as a late response and apoptosis induced cell death is an 
early response to DNA damage (Brown & Wouters, 1999). Both apoptotic and other forms of 
cell death therefore contribute to the tumour response after chemotherapy because tumour 
cells have different drug sensitivities and are susceptible to more than one type of cell death. 
Several anti-cancer drugs therefore induce non-apoptotic forms of cell death, like autophagy, 
necrosis and extrinsic senescence (Ricci et al., 2004).  
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1.6 Senescence: a major contributor to therapy resistance   
 
Hayflick and Moorehead first introduced the concept of cellular senescence by describing the 
limited potential of human diploid cells after cell passaging to divide (Hayflick and Moorehead 
1961; Lujambio, 2016). Multicellular organisms undergo cell division, which is important for 
cell survival and continued growth. Some tumour suppressor mechanisms act by diminishing 
the ability of damaged or mutant cells to develop into a tumour by eliminating the cell 
(apoptosis) or by permanently arresting the cell’s proliferation (cellular senescence) (Davalos 
et al., 2010).   
 
Cellular senescence is therefore defined as the proliferative arrest that occurs in normal cells 
after a limited number of cell divisions, but can also be referred to as a general biological 
program of terminal growth arrest (Roninson, 2003). Once senescence occurs, the cell cannot 
divide, not even through mitogen stimulation, but the cells remain metabolically active and 
show characteristic changes in morphology, including enlarged and flattened cell shapes and 
an increase in granularity. Three types of senescence have been identified: replicative, 
accelerated and oncogene-induced senescence (Gewirtz et al., 2008). The most common 
surrogate marker specific to senescent cells is senescence associated-ß-galactosidase (SA-
ß-gal) expression. X-gal can be used to stain for SA-β-gal (pH 6.0) to reflect the increased 
lysosomal mass in senescent cells (Kurz et al., 2000). 
 
During replicative senescence, cells undergo a restrictive number of divisions before they 
reach permanent growth arrest, which is determined from the shortening and structural 
alterations of telomeres, similar to the DNA damage response (Roninson, 2003). Accelerated 
senescence, characterised by the ability to rapidly induce a permanent state of growth arrest 
once cells are exposed to exogenous cytotoxic agents associated with DNA damage has the 
same biochemical and morphological features of replicative senescence (Campisi & d’Adda 
di Fagagna, 2007; Gewirtz, 2008). Accelerated senescence can also be triggered by increased 
mitogenic signalling to induce rapid cell growth arrest, which does not involve telomere 
shortening. The p53 gene is commonly implicated in senescence once DNA damage occurs 
(Stansel et al., 2002). A downstream target of p53, p21 (a cyclin-dependent kinase inhibitor), 
is therefore also a critical component in the regulation of a senescent state (Zhang, 2007). 
However, the activation of p53 and p21 in senescent cells is only temporary and after growth 
arrest, the protein levels of p53 and p21 decline. When p21 decreases, p16 (a cyclin 
dependent kinase inhibitor), is upregulated which possibly indicates that p16 maintains growth 
arrest in senescent cells (Stein et al., 1999) (Figure 1.6).  
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Figure 1.6: The p53 pathway controls cellular senescence via p21 activation (adapted from Roninson, 
2003). 
 
 
The inhibition of p21 or p53 expression reduces but does not block the senescence response 
in tumour cells after DXR treatment (Chang et al., 2002). This indicates that p53 and p21 are 
regulators of treatment-induced senescence in tumour cells, but they are not the only 
determinants thereof (Figure 1.6). Both forms of senescence (replicative and accelerated) are 
therefore essential anti-carcinogenic programmes found in normal cells (Roninson, 2003).  
 
The anti-proliferative ability of the senescence response clearly highlights this process as a 
plausible tumour suppressor mechanism, based on its ability to stop the growth of cells that 
may become mutated or malignant (Narita et al., 2006; Gewirtz, 2008). Once a cell senses 
critical levels of damage or dysfunction, the senescence program is activated (Coppe et al., 
2014). However, some studies also indicate that senescent cells often develop altered 
secretory activities that negatively influences the tumour microenvironment, which promotes 
tumourigenesis (Coppé et al., 2014).  
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Figure 1.7: The p16/Retinoblastoma (RB) pathway is a major role player in cell cycle control 
(adapted from Jayasurya et al., 2005). The RB protein is activated by Cyclin D1 or CDK4/6, which 
results in its phosphorylation. RB is then inactivated and releases transcription factors that are needed 
for cell cycle progression. The p53 protein is activated in response to DNA damage, which can induce 
apoptosis. The p21 protein is transactivated by p53, which inhibits Cyclin D1 functioning. 
 
 
In cell culture models, tumour development (in vitro) is promoted by the factors secreted from 
senescent cells by enhancing proliferation and invasiveness (Coppé et al., 2010). The 
phenomenon where senescent cells remain metabolically active but undergo changes in 
protein secretion and expression, is referred to as the senescence-associated secretory 
phenotype (SASP) and can occur in patients after they have received DNA damaging 
chemotherapy (Coppé et al., 2014). The SASP is constituted of many soluble and insoluble 
factors that affect neighbouring cells through the activation of cell surface receptors and signal 
transduction pathways. The SASP can be characterized into three components: signalling 
factors (chemokines, interleukins and growth factors), secreted proteases and secreted 
insoluble components (Coppé et al., 2010). Cytokines are known to have tumour promoting 
properties but is dependent on the relative concentration found in the surrounding cells and 
tissue (Knüpfer & Preiss, 2007).  Various cytokines are secreted by macrophages or 
lymphocytes and function to target nearby cells via a paracrine or autocrine manner (Duque 
& Descoteaux, 2014). The immune systems of breast cancer patients are significantly 
impaired, which makes them more susceptible to metastasis.  
 
The most important cytokine of the SASP is interleukin-6 (IL-6) (Ortiz-Montero, 2017). It is a 
pleiotropic pro-inflammatory cytokine which is associated with DNA damage and oncogenic 
stress-induced senescence in human and mouse melanocytes, monocytes, keratinocytes, 
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fibroblasts and epithelial cells (Chang et al., 2002). In MCF-7 cells, IL-6 is considered to have 
a pro-survival function. In addition, fibroblasts in the TME secrete IL-6, which further stimulates 
the growth of tumour cells (Esquivel-Vela´zquez et al., 2015). This cytokine often allows 
cancer cells to evade apoptosis by inducing the activation of Bcl-2 to increase resistance 
against DXR induced damage (Conze et al., 2001).  
 
Interleukin-1 (IL-1) is also upregulated by senescent cells and is especially overexpressed in 
fibroblasts as well as in epithelial and endothelial cells after chemotherapy-induced 
senescence (Chang et al., 2002). An increase in the concentration of IL-1 is responsible for 
secondary responses that cause severe damage by enhancing the production and expression 
of many cytokines. These increases can then be linked with an increase in tumour cell 
proliferation and apoptosis inhibition (Apte et al., 2006). Cytokines are responsible for growth, 
cell signalling and differentiation of both tumour and stromal cells (Lewis et al., 2006). 
Cytokines secreted by the tumour cells alter the TME for optimal growth, while cytokines 
secreted by stromal cells further enhances the growth and malignancy of cancer cells. These 
cytokines (IL-6 and IL-1) target surrounding cells like fibroblasts to trigger nuclear factor Kappa 
B (NFkB) activation which in turn allows tumour cells to enhance proliferation and block 
programmed cell death, by inhibiting the functions of caspases involved with apoptosis 
(Brasier et al., 2010). The NFkB pathway can be activated in most cell types and is therefore 
an important pro-inflammatory signalling pathway that functions to control DNA transcription, 
cell survival, immune response regulation and enhancing the expression of cytokines 
(Lawrence, 2009). Dysregulation of NFkB can therefore be linked to tumourigenesis, 
inflammation and improper immune development (Meffert et al., 2003). Senescent cells often 
overexpress insulin-like growth factor (IGF), which could possibly contribute to 
microenvironment alterations by allowing stromal cells to attract cytokines towards the TME 
to enhance an inflammatory state for optimal tumour cell proliferation (Mutgan, 2018). 
Senescent cells are able to create a permissive microenvironment that can allow cancer cells 
to grow.   Tumour development can be promoted by various factors that are secreted from 
fibroblasts in the microenvironment and can be associated with various cell types found in 
breast (Krtolica et al., 2001), skin (Herbig et al., 2004) and prostate (Ben-Porath & Weinberg, 
2005) tissue.  
 
The SASP dynamically develops over time creating a favourable environment for cancer cell 
proliferation (Coppé et al., 2008). In culture conditions, cells develop a full SASP five or more 
days after senescence has been induced while growth arrest usually occurs within 24 hours 
of damage, depending on the type of cell line. The loss of p53 due to genetic alterations results 
in a rapid SASP acquisition, which suggests that the development of the SASP is a specific 
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program triggered through genotoxic stress. Data obtained by Coppé et al suggests that the 
SASP, specifically in senescent fibroblasts, is irreversible once it has formed (Coppé et al., 
2008). However, p53 inactivation in senescent human fibroblasts with low levels of p16 can 
continue with cell proliferation, while retaining the SASP (Beausejour et al., 2003).  High levels 
of p16 expression have been known to induce senescence where the RB tumour suppressor 
pathway is positively regulated by p16. p16 induces cell cycle arrest but does not seem to 
contribute to SASP development. Cells that are induced to senesce via ectopic p16, express 
lower levels of SASP factors when compared to other senescent inducers (Coppé et al., 2008).  
 
As previously mentioned, the tumour stroma is enriched with cytokines which attract and 
activate many cell types, including cancer associated fibroblasts. These cells closely interact 
with cancer cells to remodel the extracellular matrix and promote malignancy (Mishra et al., 
2011). Similarly, senescent cells alter their tissue microenvironment towards a pro-
tumourigenic state by altering the function of neighbouring cells, which is often referred to as 
the “anti-cancer hypothesis” (Campisi, 1997; Campisi, 2005).  
 
1.7 The tumour microenvironment (TME) contributes to drug 
resistance 
 
For a long period of time, the main focus of cancer research has been on transformed tumour 
cells, which does not take the tumour microenvironment into consideration (Allinen et al., 
2004). Most current cancer therapeutics only target the cancer cells, which are able to develop 
therapeutic resistance through inherent genomic instability as previously mentioned. However, 
recent in vitro and in vivo studies have demonstrated that surrounding stromal cells such as 
fibroblasts, myofibroblasts, myoepithelial cells and leukocytes influence the growth, 
differentiation and invasive behaviour of breast carcinomas (Hu et al., 2008). 
 
Solid tumours obtained from breast epithelial tissue is supported by tumour stroma, which is 
defined as a non-malignant tumour compartment with various cell types as well as non-cellular 
components (Kucerova et al., 2013). Breast stroma is categorized by different types of cells 
like fibroblasts, adipocytes, endothelial cells, pericytes, immune cells and nerves (Wang et al., 
2017). The interaction between stroma and epithelial cells is therefore critical for proper breast 
development because breast stroma has the ability to alter the proliferation, differentiation, 
invasion, metastasis and survival of cancer cells (Mao et al., 2013). 
 
Anti-cancer agents like DXR have the ability to induce a senescent state in fibroblasts found 
in the TME (Yang et al., 2012). These senescent fibroblasts secrete a variety of bioactive 
Stellenbosch University  https://scholar.sun.ac.za
_________________________________________________________________________________ 
23 
 
molecules which promote tumour growth, metastasis, angiogenesis and drug resistance 
(Amornsupak et al., 2014). Activated fibroblasts, specifically in breast cancer, can be 
correlated with the level of aggressiveness of the disease because they have cancer 
promoting functions by guiding tumour cells through carcinogenesis via paracrine signalling, 
where proteins transmit “messages” in both directions that allow cross-talk between cancer 
cells and the stroma to occur (Aboussekhra, 2011).  It is well established that normal cells in 
the surrounding TME have the ability to promote cancer cell growth once they are altered by 
anti-cancer drugs through the secretion of various factors (Li et al., 2007; Hu et al., 2008). It 
is suggested in a study that fibroblasts secrete collagen type 1, which decreases 
chemotherapeutic uptake into cancer cells and ultimately contributes to the mechanism of 
treatment resistance. These cells, now referred to as cancer associated fibroblasts (CAFs), 
provides tumour cells with energy sources such as ketones, lactate and fatty acids, by 
increasing the secretion of cytokines to reprogram energy metabolism to become more 
glycolytic (this is achieved by the inhibition of mitochondrial metabolism), which enhances the 
metabolic efficiency of cancer cells to promote tumour growth and survival (Peiris-pagès, 
Sotgia & Lisanti, 2015).  
 
Cancer cells are therefore surrounded by a complex microenvironment, which highlights the 
rationale that the TME should become a cancer research hallmark. The tumour 
microenvironment allows the cancer cells to survive by supplying the necessary nutrients and 
allows the cells to evade cell death and to metastasize (Chen et al., 2006; Degenhardt et al., 
2006). Therefore, by fully elucidating the complex functioning and mechanisms of the TME, 
treatment strategies can be improved to avoid therapeutic resistance (Yang et al., 2015). As 
mentioned earlier, the physiological characteristics of the TME differ from those of normal 
tissue and is often described as hypoxic, nutrient deprived and inflammatory. These 
characteristics can induce autophagy through the activation of several pathways 
(Amaravadi et al., 2011). Autophagy is an essential self-eating process performed by cells to 
degrade intracellular components like organelles and aggregated proteins. The cross-talk 
between autophagy and the TME is therefore becoming an important area of clinical research 
to determine whether it contributes to chemotherapeutic resistance (Yang et al., 2015).  
 
1.8 The controversial role of autophagy in cancer development  
 
The autophagic process is defined as a catabolic process that degrades cytoplasmic 
components within a cell and thereby regulates homeostasis and cellular quality control by 
maintaining the turnover of organelles and proteins (Yang & Klionsky, 2010).  Cellular 
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homeostasis is therefore highly dependent on the balance between the biosynthesis and 
catabolism of macromolecules (You et al., 2017). Two pathways responsible for protein 
degradation exist in eukaryotic cells: the ubiquitin-proteasome pathway and the lysosomal 
pathway (Myung et al., 2001). The ubiquitin pathway selectively degrades short-lived proteins, 
while the lysosomal pathway is responsible for the degradation and recycling of long-lived 
proteins and defective organelles (Rock et al., 1994). Autophagy related cell death (ARCD) is 
therefore classified as a type of regulated cell death that depends on the autophagic 
machinery or components thereof (Galluzi et al., 2018). The autophagy response is also 
activated upon cellular stress to mediate cytoprotective, rather that cytotoxic effects. 
Therefore, by blocking autophagy with pharmacological or genetic interventions, cell death will 
be accelerated rather than delayed which is seen in many pathological disorders including 
neurodegeneration and cancer.  
 
The process of autophagy is involved in many biological processes, including cell death or 
survival, proliferation, senescence and the onset of carcinogenesis (Levine & Klionsky, 2004). 
However, the role of autophagy in cancer remains controversial (Kimchi et al., 2004; 
Kageyama & Komatsu, 2012) (Figure 1.8). The process allows cancer cells to recycle and 
restore cytoplasmic components for survival, but excessive levels of autophagy induces type 
II programmed cell death, which is considered to be a non-apoptotic form of cell death and 
can be induced by cytotoxic stimuli, such as DXR (Cagnol and Chambard, 2010; Bernard and 
Klionsky, 2013). Autophagy regulation can therefore be increased or inhibited by anti-cancer 
agents where an increase in autophagy could promote cancer cell survival and an excessive 
increase could induce cell death, depending on the tumour type and complexity of the tumour 
(Gewirtz et al., 2016).  
 
The autophagy process is initiated by the formation of a crescent shaped double membrane, 
a phagophore, which is closely associated with microtubule-associated protein 1A/1B-light 
chain 3 (LC3) (Kirisako et al., 1999).  LC3 is a soluble protein found in cultured cells as well 
as mammalian tissues, with a 17 kDa molecular mass (Tanida et al., 2008). During the onset 
of autophagy, LC3 in its cytosolic form (LC3-I) is conjugated to phosphatidylethanolamine to 
form LC3-phosphatidylethanolamine conjugate (LC3-II). LC3-II in the autolysosomal lumen is 
also degraded with the engulfed content and is therefore closely associated with lysosomal 
turnover during autophagic activity. 
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The phagophore then engulfs ubiquitinated substrates to form an autophagosome, which 
fuses with a lysosome to form an autolysosome. The autolysosome is characterized by an 
internal acidic and hydrolytic environment to degrade the content within the lumen of the 
autolysosome (Tanida et al., 2008).  
 
Figure 1.8: The controversial role of autophagy in cancer. Autophagy can promote tumour cell 
survival but can also participate in cell death (adapted from Ngabire and Kim, 2017). 
 
 
Figure 1.9: The autophagy process. The autophagy process is categorized into 5 stages: initiation, 
elongation, autophagosome formation, fusion and autolysosome formation (from Yang et al., 2015).  
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Basal levels of autophagy are regulated by the mammalian target of Rapamycin complex 1 
(mTORC1), which is a downstream effector of the Phosphoinositide 3-kinase (PI3K) pathway 
and the phosphorylation of autophagy related (ATG) gene 13 (ATG13) (He & Klionsky, 2010; 
Frankel & Lund, 2018). The mTORC1 complex monitors the nutritional state of the cell and 
maintains homeostasis by regulating the ratio between anabolic and catabolic processes.  
 
Currently, 40 autophagy related genes (ATG) that partake in autophagy or autophagy related 
processes have been identified (Klionsky et al., 2014). The first identified autophagy adaptor, 
also referred to as a cargo receptor, was p62, which is considered to be a pro-oncogenic 
regulator (Moscat et al., 2009). p62 was first discovered in mammals as a selected autophagy 
adaptor and is a multifunctioning protein that is constituted of an N-terminal Phox-BEM1 
domain (PB1), a nuclear localization signal (NLS), an LC3 interacting region (LIR), an export 
motif and a C-terminal ubiquitin associated domain (UBA) (Wang et al., 2013; Lin et al., 2013; 
Liu et al., 2016). The function of p62 is to transport ubiquitinated cargoes to the UBA or LIR 
domain for autophagic degradation (Myeku et al., 2011). The activation of autophagy will 
therefore decrease the expression of p62 because the accumulation of p62 can have 
detrimental effects (Komatsu et al., 2007). Ultimately, p62 will bind LC3-II to promote 
autophagic degradation. It also mediates the aggregation of damaged mitochondria, by 
allowing LC3-II to bind, where after damaged mitochondria can be transported to the 
autophagosome for degradation. High doses of DXR could therefore potentially increase p62 
expression to deliver the damaged mitochondria to the autophagosome to be degraded, which 
will inhibit the cancer cells to continue growing (Koleini et al., 2017).  
 
Autophagy promotes cancer cell survival by protecting the cells from oxidative stress, ROS, 
starvation and hypoxia which also allow the cancer cells to develop chemoresistance (Fiaschi 
& Chiarugi, 2012; Suman et al., 2014) (Figure 1.10). However, the functions of autophagy are 
highly dependent on the cell type, the TME and the duration of the treatment. In some patients, 
autophagy is upregulated in tumours once the treatment period is initiated, which allows the 
tumour cells to protect themselves against therapy-induced apoptosis (Brech et al., 2009).  
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Figure 1.10: Autophagy promotes cancer cell survival by protecting the cells from oxidative stress, 
ROS, starvation and hypoxia which allows the cancer cells to develop chemoresistance and continue 
growing (adapted from Yang et al., 2015).  
 
However, some studies indicate the opposite effect of autophagy and conclude that autophagy 
increases apoptotic and caspase-independent cell death in cancer cells (Colell et al., 2007). 
In most cases, autophagy sustains cancer cell viability once the apoptotic process becomes 
defective (Lum et al., 2005; Karantza-Wadsworth et al., 2007). Defective apoptosis allows the 
cancer cells to tolerate long term metabolic stress (White et al., 2007). Cells with PI3K 
mutations or Akt (protein kinase B) activation (characteristic during tumour development) is 
therefore dependent on autophagy for energy homeostasis and survival. Proliferating tumour 
cells are highly disadvantaged once autophagy is inhibited because compensatory 
mechanisms must be implemented for cancer cell survival (Mah et al., 2012).  
 
It is well established that autophagy is regulated by many signalling pathways, including the 
PI3K-mTOR signalling pathway, which is a key regulator of the autophagic process (Klionsky, 
2005; Esclatine et al., 2009; He and Klionsky, 2009). As mentioned previously, the PI3K 
pathway is responsible for many cellular regulatory processes including cell differentiation, cell 
survival and proliferation (Engelman et al., 2006; Liu et al., 2009). The PI3K pathway is 
activated in most human cancers, but multiple components of the PI3K pathway are easily 
mutated or modified, which disrupts autophagy regulation and can potentially result in the 
onset of tumourigenesis (Liu et al., 2009). The PI3K pathway is therefore an ideal target for 
cancer therapy (Massacesi et al., 2016). The first PI3K pathway-targeted agents were 
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rapamycin analogues, which allosterically inhibit mTORC1 (Dienstmann et al., 2014). Several 
PI3K-inhibitors are currently under clinical investigation, including pan-PI3K inhibitors that 
target all four isoforms of PI3K, as well as isoform selective inhibitors like copanlisib, pictilisib 
and taselisib (Dienstmann et al., 2014). However, by inhibiting the PI3K pathway, high mobility 
group box 1 (HMGB1)-induced autophagy is also significantly inhibited (Sun et al., 2015). 
 
1.9 High mobility group box 1 promotes an inflammatory state in 
cancer development   
 
HMGB1 was discovered 40 years ago in calf thymus and was named for its fast-
electrophoretic mobility in polyacrylamide gels (Zhang et al., 2012). Currently, it is referred to 
as a non-histone chromosomal protein that is ubiquitously found in all vertebrate nuclei that 
binds double-stranded DNA, independent of sequence specificity (Sun et al., 2015).  
 
The HMGB1 protein is found in most cell types and is normally confined in the nucleus where 
it regulates protein transcription, by functioning as a nuclear cofactor (Sun et al., 2015). 
HMGB1 is passively released from necrotic cells and is also actively secreted by inflammatory 
cells, which binds to several receptors like the receptor for advanced glycation end products 
(RAGE) and Toll-like receptors 2 and 4 (TLR2 and TLR4) (Lotze et al., 2005; Dong et al., 
2007). HMGB1 is therefore implicated in many disease states including sepsis, 
neurodegeneration and cancer (Wang et al., 2004; Ellerman et al., 2007; Sparvero et al., 
2009). Similarly, a few studies have also indicated that the levels of HMGB1 and RAGE are 
overexpressed in various human neoplasms (prostate, pancreatic and colorectal cancer), 
when compared to the surrounding normal epithelium (Pardo et al., 2006; Volp et al., 2006). 
The overexpression of HMGB1 is associated with the hallmarks of cancer: unlimited replicative 
capacity, angiogenesis, resistance to growth inhibitors, evasion of apoptosis, inflammation 
and tissue invasion and metastasis (Hanahan & Weinberg, 2000). HMGB1 is therefore the 
prototypic Damage Associated Molecular Pattern (DAMP) associated with an acute and 
chronic inflammatory response and wound repair (Land et al., 1994; Matzinger, 2004). DAMPs 
are endogenous molecules that are released into the extracellular space when tissue damage 
or cellular stress is present (Alvarez & Vasquez, 2017). Pattern recognition receptors (PRR) 
identify these molecules to induce inflammation and an immune response, without an infection 
present. HMGB1 overexpression is therefore strongly correlated with tumour invasiveness in 
cancer patients. A few studies have suggested that the growth of breast cancer cells in vitro 
is promoted by HMGB1, however the exact role of HMGB1 in breast cancer patients is not yet 
fully elucidated (Jiao et al., 2007; Chalmers et al., 2013).  
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As previously mentioned, cancer cell death can be induced by many factors, including 
chemotherapy (anti-cancer treatments). Tumour cells treated with chemotherapy release 
HMGB1 to induce inflammation, by stimulating the release of TNF-α and IL-1β (Bustin, 2002; 
Dong et al., 2007). When HMGB1 is present in the extracellular medium, it indicates that the 
cells have become stressed or have died. These cells are then able to alert other cells in the 
nearby environment to avoid the immediate danger (Bianchi, 2009). Furthermore, HMGB1 is 
also suggested to play a major role in apoptosis, depending on the cell type and stress inducer 
(Tang et al., 2010). HMGB1 protects mammalian cells against the damaging effects of death 
stimuli, like radiation by avoiding CD95 activation and caspase 8- and Bax-induced apoptosis 
(Brezniceanu et al., 2003). To establish HMGB1’s role in treatment resistance, Lang et al 
indicated that HMGB1 knockdown in MEFs causes hypersensitivity to UV radiation, which 
supports the ability of HMGB1 to protect cells against cell death or apoptosis (Lang et al., 
2008).  
 
Furthermore, Sun et al investigated HMGB1 expression in both tissue and serum in breast 
cancer. HMGB1 expression was greater in breast cancer tissue, when compared to the 
surrounding normal tissue and thereby supports the role of HMGB1 in tumorigenesis (Sun et 
al., 2015). The authors also provided possible mechanisms that allows HMGB1 to induce 
tumour development:   
 
1: HMGB1 overexpression causes certain gene mutations that may lead to certain tumour 
phenotypes.  
2: High levels of HMGB1 promotes tumour growth by preventing apoptosis induction (Muller 
et al., 2004). 
 
Cancer patients often develop resistance towards chemotherapeutic drugs after a few years, 
which allows the cancer to reoccur (Dalton, 1997). As mentioned earlier, DXR induces cell 
death or growth arrest, but DXR resistance often occurs in advanced tumours, which result in 
a poor prognosis (Kruh & Goldstein, 1993). The involvement of autophagy in DXR resistance 
is therefore being extensively studied and the inhibition or activation of autophagy can 
therefore partly overcome DXR resistance in many cancer types, which suggests that 
autophagy modulation can be a promising strategy to overcome DXR resistance (Chen et al., 
2017).  
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1.10 Autophagy contributes to DXR resistance in cancer  
 
Autophagy causes cell death or will allow cancer cells to survive, depending on the treatment 
duration and the severity thereof (Aydinlik et al., 2017).  Several studies suggest that during 
nutrient deficiency, many therapeutics such as tamoxifen (a chemotherapeutic agent) induces 
autophagy as a pro-survival mechanism to ensure that cancer cells continue growing 
(Zarzynska et al., 2014).  
 
However, in some studies, autophagy is considered to be a tumour suppressive mechanism 
and is therefore characterised as being cytotoxic towards cancer cells. DXR is most commonly 
used to treat triple negative breast cancer (TNBC) and studies indicate that once cytotoxic 
autophagy is induced, the ability of DXR to kill cancer cells is diminished (Tani et al., 2015). 
Many clinically approved anti-cancer agents, like DXR, upregulate autophagy in cancer cells 
in vitro and by inhibiting autophagosome formation or autophagy signalling pathways (PI3K 
and mTOR), cancer cell death can be promoted (Kondo et al., 2005).  
 
DXR is therefore commonly used as an anti-cancer drug worldwide to kill cancer cells through 
apoptosis by inducing DNA damage (Lee et al., 2002). Moderate doses of DXR can also 
induce a senescence phenotype in cells, especially in normal fibroblasts (Roninson, 2003). In 
2009, Young et al reported that autophagy-related genes are upregulated during oncogene 
induced senescence and that by inhibiting autophagy, the onset of a senescence phenotype 
can be delayed (Young et al., 2009).  
 
1.11 The role of apoptosis and senescence in autophagy  
 
Cross talk between autophagy and apoptosis is well-established, however, there is little 
evidence to support the potential of a direct relationship between autophagy and senescence 
(Gewirtz, 2007; Thorburn 2008).  When autophagy is inhibited, cancer cells undergo 
apoptosis, but dysregulated apoptosis is commonly present in human cancers and cancer 
cells die by other cell-death mechanisms (Degenhardt et al., 2006). It is therefore suggested 
that autophagy is another form of cell death in apoptosis resistant cancer cells, but the exact 
mechanisms are not known (Maiuri et al., 2007).  Cross talk between autophagy and apoptosis 
exist because the two pathways share the same mediators for upstream or downstream 
signalling. Studies therefore suggest that autophagy is linked with the extrinsic pathway, 
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mediated by p62/Sequestome 1 (SQSTM 1) when it binds and activates caspase 8 to enhance 
TRAIL-mediated apoptosis (Jin et al., 2009).  
 
The link between senescence and autophagy has not fully been elucidated, but senescence 
and autophagy have many similar characteristics and processes that have the same outcome 
for cells. Both senescence and autophagy induce responses that can either be cytoprotective 
or cytotoxic after chemotherapy or radiation (Gewirtz, 2013). The study of Young et al was the 
first to identify a possible relationship between autophagy and senescence in fibroblasts 
(Young et al., 2009). They concluded that autophagy can delay the oncogene-induced 
senescence response. To further support the above-mentioned findings, David Gewirtz 
indicated that autophagy and senescence is regulated by overlapping signalling pathways 
such as ROS production, induction of p53 and p21 and dephosphorylation of Retinoblastoma 
(RB) protein (Gewirtz, 2007). Other groups have also reported that autophagy promotes 
senescence by overexpressing CDK inhibitors (p16 and p21) in both fibroblasts and breast 
cancer cells (Capparelli et al., 2012). However, it is also known that autophagy supresses 
senescence to maintain cellular homeostasis, especially during excessive oxidative stress 
levels or during mitochondrial dysfunction, where uncoupling mitochondria reduces 
superoxide generation to limit the senescence response (Kwon et al., 2017). 
 
Furthermore, a senescent state is also associated with tumour dormancy (Gewirtz, 2007). 
Tumour dormancy generally occurs at the primary tumour site, where cells were not 
successfully removed during radiation or surgery. These cancer cells are also able to remain 
dormant in brain or bone tissue once the cells have metastasized (Gewirtz et al., 2009). Once 
these tumour cells enter an active dividing state, the cells will continue to grow, which results 
in cancer recurrence.  
 
Autophagy induces an effective immune response in cancer cells exposed to 
chemotherapeutics and similarly during senescence, the cell induces a prolonged state of 
growth arrest to avoid stress induced toxicity (Michaud et al., 2011). Both processes are 
therefore able to evade cellular death. In 2009, Yang et al reported that autophagy related 
genes are upregulated in oncogene-induced senescence and that autophagy inhibition delays 
the senescent phenotype, which indicates that these cells reflect efforts to try and evade the 
direct cell death response (Yang et al., 2009). In addition to the above-mentioned study, 
Goehe et al indicated that senescence is temporarily blocked during pharmacological 
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inhibition of autophagy (Goehe et al., 2012). It seems that autophagy accelerates the 
senescence response by providing energy sources, but the authors concluded that 
senescence can occur independently from autophagy.  
 
Although a direct link between senescence and autophagy has not been established, some 
studies have reported that both processes signal the immune system to eliminate a growing 
tumour because both are associated with an inflammatory response and the production of 
various cytokines (Ewald et al., 2010; Michaud et al., 2011). In addition to the above 
mentioned, it is also suggested that autophagy and senescence are regulated through 
overlappingexc signalling pathways such as ROS production, the induction of p21 and p53 
and dephosphorylation of RB and the overexpression of several CDK inhibitors (p16, p19 and 
p21) has shown to activate the autophagic pathway in several cell types (Gewirtz, 2007). In 
some cases, autophagy suppresses senescence to maintain cellular homeostasis especially 
during excessive oxidative stress levels or during mitochondrial dysfunction, but remains to 
be further elucidated (Young et al., 2009; Kwon et al., 2017). Apoptosis, senescence and 
autophagy therefore interconnect in cancer development and growth and could alter the 
response of tumours to anti-cancer therapy (Powlaska et al., 2018).  
 
Normal cells, like fibroblasts, in the surrounding TME are also affected by DXR and several 
studies have shown that once fibroblasts adopt a senescence phenotype, apoptosis induction 
in cancer cells is limited (Tao et al., 2017; Wang et al., 2017). Cancer cells coevolve with the 
TME, therefore the ability of autophagy to modulate interactions between cells in the TME is 
a potential factor in determining whether autophagy inhibition can be effective in cancer 
treatment (Levy et al., 2017).  
 
1.12 The role of autophagy in the tumour microenvironment (TME) 
 
As mentioned previously, the TME contributes to cancer cell survival, metastasis and invasion 
(Yang et al., 2015). The TME and normal tissues differ physiologically, where the TME has 
been described as nutrient deprived, hypoxic and inflammatory (Amaravadi et al., 2011). 
Studies have shown that between 50-60% of tumours survive in hypoxic conditions and one 
possible mechanism that contributes to their ability to survive is by increasing the activation of 
the autophagic pathway (Vaupel et al., 2007).  
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Tumour progression in the TME is greatly associated with the onset of inflammation 
(Coussens et al., 2002). Chronic inflammation favourably promotes tumorigenesis and 
enhances the ability of cancer cells to metastasize (Ngabire & Kim, 2017). Highly plastic 
leukocytes, referred to as macrophages, enter various tissues under inflammatory conditions 
and adopt different phenotypes and functions depending on the cues that they receive from 
the environment (Ariel et al., 2012). Macrophages in the TME are recruited from monocytes 
found in blood vessels and are polarized into tumour associated macrophages (TAMs). The 
two known phenotypes for TAMs are M1 macrophages that are pro-inflammatory and M2 
macrophages, which are anti-inflammatory (Franklin et al., 2014).   Inflammatory cytokines 
such as IL-6, IL-10 and TGF-β are released by TAMs and contributes to the development of 
cancer by limiting apoptosis in the TME. Cytokines therefore play a major role in the 
development of chronic inflammation to generate a pro-tumour response (Ngabire & Kim, 
2017). Chronic inflammation is generally also associated with an increase in oxidative stress 
which activates NF-kB to stimulate the onset of autophagy to allow cancer cell growth (Joven 
et al., 2014). Once autophagy is activated, other cell death pathways like PARP-mediated cell 
death induced by DXR becomes impaired, which will allow the cancer cells to continue 
proliferating (Degterev et al., 2008).  
 
Tumour resistance to chemotherapy is therefore often associated with autophagy due to the 
enhanced ability of cancer cells to evade cell death and to rapidly proliferate (Yang et al., 
2015). By inhibiting autophagy, chemosensitivity could possibly be enhanced, therefore 
elucidating the impression that a combination of cytotoxic drugs and an autophagy inhibitor 
could be a possible treatment therapy for breast cancer patients (Yang et al., 2011). 
 
1.13 Inhibition of autophagy can enhance cancer cell death  
 
Autophagy functions to control homeostasis in all living organisms and dysregulation of this 
pathway could therefore support and enhance tumour development (White & DiPoala, 2009; 
Katayama et al., 2007). Autophagy allows oncogenic transformation to occur by limiting the 
occurrence of chronic inflammation, which is responsible for the release of pro-inflammatory 
HMGB1 (stimulates NFκB-induced transcription). Studies therefore suggest that autophagy 
increases the ability of cells to tolerate stress, which promotes tumour survival (Guo et al., 
2011). Inactivation of autophagy (by activating the PI3K pathway and mTOR) prevents the 
cells from surviving during metabolic stress (Tanida et al., 2008). Therefore, in cells with a 
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defect in apoptosis, this could ultimately result in necrosis mediated cell death (Elmore, 2007). 
However, the specific trigger that activates the onset of necrosis is unknown.  
 
Many authors have concluded that autophagy is required to maintain protein and organelle 
quality control and basal levels of autophagy are present in normal physiological conditions 
(Das et al., 2012; Mathew et al., 2007). Cancer cells with apoptosis defects could result in 
DNA and genome damage, which contributes to the tumour promoting properties of autophagy 
(Tanida et al., 2008). Once genome damage occurs, cellular functions that maintain genome 
integrity (DNA replication and repair) is severely damaged.  
 
The ability to inhibit autophagy therefore has great potential as a target for cancer therapy, 
once apoptosis resistant cancer cells become sensitized to metabolic stress (Maycotte & 
Thorburn, 2011). Conventional therapies such as surgery and chemotherapy can potentially 
disrupt tumour architecture and vascularization and remaining tumour cells could then become 
susceptible to metabolic stress and autophagic inhibitory therapy, which could prevent tumour 
regrowth and metastasis (Hayat, 2013). Pharmacological inhibitors of autophagy like 
Bafilomycin A1 and Chloroquine are used in cells and tissues to determine whether autophagy 
has protective or damaging effects in normal and pathological states because of its 
controversial role in cancer development (Maycotte & Thorburn, 2011). Recently, a clinical 
trial in America aimed to determine the effects of autophagy inhibition with Chloroquine in 
DCIS and whether it will reduce the ability of the cancer cells to survive. Participants received 
either chloroquine standard dose (500 mg/week) or chloroquine low dose (250 mg/week) for 
1 month prior to surgical removal of the tumour (Martinez-Outschoorn et al., 2010). 
 
Bafilomycin was first isolated from the mycelium of Streptomyces and was defined as a 
macrolide antibiotic able to prevent or inhibit the growth of fungi, yeast and gram-negative 
bacteria (Dodsen et al., 2013). The ability of Bafilomycin to inhibit vacuolar ATPase (V-
ATPase), the enzyme responsible for vesicular acidification and pH control in the lysosome, 
allowed for its functional classification (Lee et al., 2012). During autophagy, lysosomes and 
autophagosomes fuse together and Bafilomycin can prevent this fusion by inhibiting V-
ATPase. Therefore, inhibition of the fusion process will ultimately prevent the autophagic flux 
from occurring (Bowman et al., 1988; Yosimori et al., 1991). 
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The ability of cancer cells to develop resistance against chemotherapy treatment is still 
however a major concern (Housman et al., 2014). Chemotherapy kills cancer cells by 
effectively stopping the cell division process. Anti-cancer drugs damage the RNA or DNA that 
is responsible for the cancer cell being able to copy itself during cell division (Lodish et al., 
2000). If the cancer cells are unable to divide, they die. However, the proliferation of a tumour 
cell line can be enhanced in vitro by conditioned media (CM) obtained from fibroblasts, which 
possibly indicates that soluble factors are present in the CM, which will allow the cancer cells 
to evade apoptosis (Pistone et al., 2013). Furthermore, senescent cells within in the tumour 
microenvironment communicate with neighbouring cells by secreting factors that constitute 
the SASP (cytokines, chemokines, and growth factors) (Lujambio et al., 2016). Senescent 
fibroblasts therefore have the ability to enhance the proliferation of cancer cells by secreting 
these molecules. A limitation of current cancer therapies like chemotherapy and radiation is 
that many cancers develop resistance to apoptosis and therapies that target alternative 
pathways should therefore be considered (Fung et al., 2008; Maycotte & Thorburn, 2011). 
However, the role of autophagy in tumourigenesis still remains controversial. Increased 
autophagy induces autophagic cell death in apoptosis defective cells, but inhibiting autophagy 
could also prevent autophagy mediated resistance against chemotherapy (Shimizu et al., 
2004; Akar et al., 2008). Therefore, for the future development of effective cancer therapy with 
minimal side effects, it is important to determine whether autophagy is a protective mechanism 
that decreases cancer cell death or if it promotes apoptotic cancer cell death.  
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1.14 Hypothesis  
 
Based on the current literature, we hypothesize that fibroblasts can secrete paracrine factors 
that affects breast cancer growth and DXR resistance, however, these effects might differ 
when senescence and apoptosis is induced in the fibroblasts.  
 
1.15 Aim  
 
The aim of this study is to assess the effects of conditioned media harvested from senescent 
and apoptotic fibroblasts on breast cancer cells to determine whether senescent fibroblasts 
and autophagy contribute to the ability of breast cancer cells to evade apoptotic cell death. 
 
1.16 Objectives: 
 
- To treat mouse embryonic fibroblasts (MEFs) with DXR and determine a concentration 
that induces apoptosis and senescence in these cells by performing cell viability and 
senescence-associated β-galactosidase assays as well as assessing the protein 
expression of markers for each process with western blots. 
- To generate conditioned media from MEFs treated with optimised DXR concentrations. 
- To determine the sensitivity of mouse breast cancer cells (E0771 cells) to DXR when 
exposed to conditioned media from apoptotic and senescent MEFs. 
- To determine the effect of conditioned media treatment and autophagy inhibition in 
E0771 cells. 
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Chapter 2: Methods and Materials 
 
2. Study design  
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Figure 2.1: Study design. Conditioned media for treatment groups was generated by treating MEFs 
with DXR. E0771 cells were treated with the conditioned media groups and cell viability and apoptotic 
and autophagic activity was assessed.  
 
2.2 Cell culture 
 
MEFs and mouse E0771 breast cancer cells were used to perform experiments. The cells 
were cultured in Dulbecco's Modified Eagle's medium (DMEM), supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Penstrep (now referred to as growth medium). The cells were 
cultured in T75 flasks, respectively, and was maintained at 37°C in a 5% CO2 incubator and 
were routinely sub-cultured at 70-80% confluency. Both cell lines were allowed to grow in the 
T75 flasks until they reached 80% confluency and were then split into the appropriate plates 
with new growth medium for various experiments. Subculturing of cells was achieved by 
removing the growth medium, followed by incubation with 4 ml 0.25% Trypsin at 37°C until the 
cells were detached completely from the flask. 
 
2.3 Experimental protocol for MEFs  
 
2.3.1 Treatment preparations  
 
MEFs were grown in T75 flasks and was categorized into six groups (Table 2.1). The following 
treatment protocols were performed to generate the desired groups of conditioned media 
(control, apoptosis and senescence) which was used to treat E0771 cells (refer to 2.2.4).  
 
Table 2.1: MEFs were categorized into three groups and were treated accordingly to generate 
conditioned media.  
Group number  Group name  Treatment  
Group 1 Conditioned media control (CM-C) None 
Group 2 Conditioned media apoptosis (CM-A) 1 µM DXR (24 hours) 
Group 3 Conditioned media senescence (CM-S) 2 µ DXR (4 hours) 
 
Doxorubicin hydrochloride was obtained from Sigma. A stock solution was prepared by 
dissolving the powder in pure DMEM and stored at -20°C. The desired concentration of DXR 
was diluted into complete growth media before each experiment.  
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For apoptosis induction, upon reaching 80% confluency, MEFS were split and 100 000 MEFs 
were seeded into 6-well plates (10 cm2) for protein extraction (see section 2.3) and 5000 MEFs 
were seeded into 48-well plates for 24 hours to determine cell viability (see 2.2.3). The 
following day, growth medium was removed and 1 µM of DXR was added and removed after 
24 hours, followed by a protein harvest.  
For senescence induction, upon reaching 80% confluency, 75 000 MEFs were seeded into 6-
well plates (10 cm2) supplemented with growth medium. The next day, 2 µM of DXR was 
added and removed after 4 hours. Fresh growth media was added to the wells and cells 
remained in the incubator. Protein harvests were performed on days 1, 2, 4, 8 and 12 after the 
DXR treatment was removed. The SA-β-Gal stain (Sigma) was performed on day 12 
(Appendix A).  
 
2.3.3 Determination of cell death  
 
2.3.3.1 MTT Assay  
 
To determine the viability of MEFs after the treatment period, an MTT assay (Mosmann, 1983) 
was performed. Viable cells with an active metabolism have NAD(P)H-dependent 
oxidoreductase enzymes which has the ability to convert MTT (yellow tetrazole) into purple 
Formazan crystals which accumulates as an insoluble precipitate inside cells. Formazan 
crystals must therefore be solubilized before measuring absorbance. MEFs were categorized 
into groups and seeded into 48-well plates at a seeding density of 7000 cells per well and was 
incubated in 200 µl growth medium for 24 hours. The following day, growth medium was 
aspirated and different concentrations of DXR was administered into the wells and the cells 
were incubated in a 5% CO₂ incubator for 24 hours at 37°C. After the treatment period was 
completed, 0.1 mg/ml MTT solution (made up in 0.1 M PBS) was added into the wells and 
incubated for one hour in a 5% CO₂ incubator. Cell viability was then determined by 
solubilizing Formazan in an Isopropanol-0.1% Triton-X solution. The absorbance was then 
measured at 595 nm in a plate reading spectrophotometer. The number of viable cells was 
expressed as a percentage (%) of the total number of cells.  
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
_________________________________________________________________________________ 
40 
 
2.3.4 Conditioned media  
 
As mentioned previously, different groups of conditioned media were generated and was used 
to treat E0771 cells. For control conditioned media (CM-C), 30 ml of growth medium in a T75 
flask (no cells) was incubated in a 5% CO₂ incubator for 24 hours. After the treatment duration 
was completed, the media was collected into 50 ml Falcon tubes, snap frozen in liquid nitrogen 
and stored at -80°C.  
 
For senescence conditioned media (CM-S), 563 000 MEFs were seeded into T75 flasks (x2) 
and were grown overnight in 10 ml growth medium in a 5% CO₂ incubator. Thereafter, the 
growth medium was removed and MEFs were treated with 2 µM of DXR for four hours in a 
5% CO₂ incubator and CM was collected on day 7, 10 and 13. Media was collected from the 
T75 flasks and centrifuged at 5000 rpm for 10 minutes at 4°C. The media was carefully 
transferred to a new tube and filtered with a 0.2 µm filter. The CM was then snap frozen and 
stored at -80°C until use.  
 
For apoptosis CM (CM-A), 563 000 MEFs were seeded into T75 flasks (x3) and was grown 
overnight in 10 ml growth medium in a 5% CO₂ incubator. Thereafter, growth medium was 
removed and MEFs were treated with 1 µM of DXR for 24 hours in a 5% CO₂ incubator. After 
the treatment period, CM was collected from the T75 flasks and centrifuged at 5000 rpm for 
10 minutes at 4°C. The media was carefully transferred to a new tube and filtered with a 0.2 
µm filter. The CM was then snap frozen and stored at -80°C until use. 
 
2.4 Protein extraction and quantification  
 
Following treatment protocols mentioned in 2.2.1, cells drained and placed on ice. The cell 
monolayers were then washed twice with 1 ml of ice-cold PBS (Appendix B). Total cell protein 
was extracted by incubating the cells in 1 ml of modified radio-immuno precipitation (RIPA) 
buffer (Appendix C) containing 1x complete™ protease inhibitor cocktail (Roche), 1 mM NaF, 
1 mM Na3VO4 and 1 mM PMSF. A cell scraper was used to detach cells from the surface of 
the wells and the cells were transferred to chilled Eppendorf tubes. The suspension from 
triplicate wells were pooled and sonicated for 10 seconds at 5 amplitudes. After the foam 
settled, the suspension was centrifuged and the supernatant was carefully collected and 
placed into a new pre-cooled Eppendorf tube and stored at -80°C. Protein content was 
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quantified using the Bradford protein determination method before the preparation of cell 
lysates. 
 
2.4.1 Bradford Assay  
 
A Bradford assay was performed to determine the concentration of protein lysates (Bradford, 
1976). A standard curve consisting of six incremental concentrations was prepared from a 2 
mg/ml bovine serum albumin (BSA) solution. Bradford samples were prepared with 5 µl of the 
protein lysate. Absorbance was measured on a spectrophotometer set to 595 nm. The 
absorbencies were plotted on a graph generated with the standard curve in Microsoft Excel.  
All samples were prepared in duplicate. For protein quantification, whole cell lysates were 
thawed and were centrifuged at 4°C and 8000 rpm for 2 minutes. A 200 mg/ml BSA working 
solution was prepared and Bradford standards were prepared in duplicate. A complete step 
by step protocol for Bradford assay is included in Appendix D. 
 
2.4.2 Sample preparation  
 
After protein quantification (determined by Bradford assay), aliquots containing 50 µg of 
protein were prepared for each sample. Lysates were diluted in Laemmli sample buffer (150 
μl mercaptoethanol and 850 μl sample buffer) (Appendix E) and boiled for 5 minutes at 95°C. 
The prepared samples were stored at -80°C for future analysis by western blotting. 
 
2.4.3 SDS-Page and western blot analysis 
 
Prepared lysates were separated on 12% gels by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) (TGX Stain-Free™ FastCast™ Acrylamide kit, Biorad). 
Molecular weights of specific bands were determined by loading 4 µl of a protein marker ladder 
into the first lane of each gel. Previously prepared samples were dry boiled for 5 minutes at 
95ºC before 50 µg of protein was loaded into each well. For the first 10 minutes, proteins were 
separated at 90 V, followed by approximately 90 minutes at 110 V (Mini Protean System, Bio-
Rad, Hercules). After electrophoresis, separated proteins were transferred (Trans-blot 
Turbo™ RTA Transfer Kit, PVDF Biorad) onto PVDF membranes and blocked in 5% fat free 
milk in TBS-Tween (TBS-T) for one hour at room temperature with gentle agitation to avoid 
non-specific binding before overnight incubation at 4°C with specific primary antibodies (Table 
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2. 2) (diluted in TBS-T). The following day, membranes were washed in TBS-T three times for 
5 minutes. After the washing step, membranes were incubated in anti-rabbit horseradish 
peroxidase-conjugated secondary antibody for 1 hour at room temperature on a roller. After 
secondary antibody incubation, membranes were washed 3 times for 5 minutes in TBS-T. 
Antibodies were detected using the ECL (Biorad) detection kit. Exposed bands were quantified 
using Image Lab software™ (Biorad). Exposed bands were quantified relative to the total 
protein present in each lane. A stain free total protein analysis was used. The technology uses 
a trihalo compound that is directly incorporated into the gel. After UV exposure, the compound 
modifies tryptophan residues in proteins which cause them to fluoresce. This fluorescent 
signal was then detected by a CCD camera, after the gel was transferred to a PVDF 
membrane. A complete step by step protocol for SDS-PAGE and western blot analysis is 
included in Appendix F. 
 
Table 2.2: Antibodies used in western blot analysis for MEFs. 
Antibody  Size  Concentration  
Apoptosis    
Cleaved caspase 3  17 kDa 1:1000 
Cleaved caspase 8 57 kDa 1:1000 
Cleaved caspase 9  35-37 kDa  1:500 
PARP 89 kDa 1:1000 
Senescence   
MCM2 102 kDa 1:10 000 
p53 53 kDa 1:500 
p21 21 kDa 1:500 
p16 16 kDa 1:1000 
RB 106 kDa 1:1000 
 
 
2.5 Experimental protocol for E0771 cells 
 
2.5.1 Treatment preparations 
 
E0771 cells were grown in T75 flasks until 80% confluency and were split into 6-well plates 
for the appropriate experiments. Control, apoptosis and senescence conditioned media (CM) 
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generated from MEFs (section 2.2.4) were used to treat E0771 cells, alongside with DXR. 
E0771 cells were categorized into 6 groups (Table 2.3). 470 000 cells (per well) were seeded 
into 6-well plates and 7000 cells (per well) were seeded into 48-well plates (for cell viability) 
and incubated in growth medium for 24 hours in a 5% CO₂ incubator. The following day, 
growth media was aspirated and cells were treated with the appropriate generated CM for 24 
hours in a 5% CO₂ incubator. Afterwards, cell viability (section 2.2.3.1) and protein extraction 
(section 2.3) were performed as mentioned above. Western blot analysis (section 2.3.3) was 
used to determine the expression of apoptotic and senescence markers in the E0771 cells 
(see table 2.2).  
 
Table 2.3: E0771 cells were categorized into 6 groups and treated with conditioned media generated 
from MEFs.  
Group 
number 
Group name  Treatment  Duration  
Group 1 Conditioned media Control 
(CM-C) 
None  24 hours  
Group 2  Conditioned media Control & 
DXR (CM-C-DXR) 
1 µM DXR  24 hours 
Group 3 Conditioned media apoptosis 
(CM-A) 
None 24 hours 
Group 4 Conditioned media apoptosis 
& DXR (CM-A-DXR) 
1 µM DXR 24 hours 
Group 5 Conditioned media 
senescence (CM-S) 
None 24 hours 
Group 6 Conditioned media 
senescence& DXR (CM-S-
DXR) 
1 µM DXR 24 hours 
 
 
2.5.2 Determination of autophagic induction 
 
Autophagy was determined by analysing the expression of LC3 and p62. E0771 cells were 
grown in T75 flasks and were categorized into different treatment groups. After reaching 
confluency, 470 000 cells per well were seeded into 6-well plates for protein extraction (see 
section 2.3) and 7000 cells were seeded into 48-well plates to determine the effects of 
autophagy on cell viability (see section 2.2.3.1). Bafilomycin (400 nM), an autophagy inhibitor, 
was added 4 hours prior to the above-mentioned experiments to measure autophagic flux. 
Bafilomycin prevents maturation of autophagic vacuoles by inhibiting fusion between 
autophagosomes and lysosomes through the inhibition of vacuolar H+ATPase. 
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Table 2.4: E0771 cells were categorized into 12 groups and treated with conditioned media generated 
from MEFs as well as Bafilomycin to determine autophagic flux. 
Group 
number 
Group name  Treatment  Duration 
Group 1 Conditioned media Control (CM-C) None  24 hours  
Group 2 Conditioned media Control & Baf 
(CM-C-Baf) 
Baf (400 nM)  24 hours  
Baf: 4 hours prior to 
end of treatment 
Group 3 Conditioned media Control & DXR 
(CM-C-DXR) 
1 µM DXR  24 hours 
Group 4 Conditioned media Control & DXR & 
Baf (CM-C-DXR-Baf) 
1 µM DXR  
400 nM Baf 
DXR: 24 hours  
Baf: 4 hours prior to 
end of treatment  
Group 5 Conditioned media apoptosis (CM-
A) 
None  24 hours 
Group 6 Conditioned media apoptosis & Baf 
(CM-A-Baf) 
Baf (400 nM) 24 hours  
Baf: 4 hours prior to 
end of treatment 
Group 7 Conditioned media apoptosis & 
DXR (CM-A-DXR) 
1 µM DXR 24 hours 
Group 8 Conditioned media apoptosis & 
DXR & Baf (CM-A-DXR-Baf) 
1 µM DXR  
400 nM Baf 
DXR: 24 hours  
Baf: 4 hours prior to 
end of treatment 
Group 9 Conditioned media senescence 
(CM-S) 
None  24 hours 
Group 10 Conditioned media senescence & 
Baf (CM-S-Baf) 
Baf (400 nM) 24 hours  
Baf: 4 hours prior to 
end of treatment 
Group 11 Conditioned media senescence & 
DXR (CM-S-DXR) 
1 µM DXR 24 hours 
Group 12 Conditioned media senescence & 
DXR & Baf (CM-S-DXR-Baf) 
1 µM DXR  
400 nM Baf 
DXR: 24 hours  
Baf: 4 hours prior to 
end of treatment 
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2.5.3 Western blot analysis for autophagy and proliferation 
 
The protocol for the western blot analysis in this section is described in section 2.3. A seeding 
density of 470 000 cells per well in 6-well plates was used for this experiment. After the cells 
were seeded into the appropriate plates, they were allowed to grow for 24 hours in a 5% CO₂ 
incubator. Afterwards, the cells were treated as indicated in Table 2.4. For the determination 
of autophagy, membranes were incubated overnight at 4°C with specific primary antibodies 
(diluted in TBS-T) (Table 2.5). 
 
Table 2.5: Antibodies for autophagy and proliferation used in western blot analysis for E0771. 
Antibody  Size  Concentration 
Autophagy    
LC3 II 17 kDa 1:1000 
p62  62 kDa 1:1000 
Proliferation    
Phosphorylated Akt 60 kDa 1:1000 
Total Akt  60 kDa  
Phosphorylated ERK1/2 44/42 kDa 1:2000 
Total ERK 1/2 44/42 kDa 1:1000 
 
2.5.4 LC3 and p62 Immunocytochemistry 
 
After reaching 80% confluency, 70 000 cells were seeded onto glass coverslips in 6-well plates 
and was treated with conditioned media (control, apoptosis and senescence) for 24 hours and 
Bafilomycin for 24 hours as previously described. The media was aspirated from the wells and 
placed onto microscope slides, followed by a PBS wash step (3 times). The cells were then 
fixed with 4% Formaldehyde for 10 minutes, followed by another fixation period with 0.1% 
Triton-X for 10 minutes. This was followed by another PBS wash step (3 times). Afterwards, 
the cells were blocked in 1% BSA for 60 minutes and was then incubated in primary antibody 
overnight at 4 °C. After primary incubation, the cells were washed with PBS (3 times) and 
incubated in secondary antibody (Donkey anti-Rabbit IgG (H+L) Secondary Antibody Alexa 
Fluor 568 [ThermoFisher Scientific, Cat A10042]) prepared in PBS for 60 minutes, protected 
from light.  Afterwards, nuclei were counterstained with 10 mg/ml Hoechst (1:200) prepared in 
PBS for 10 minutes. Followed by another wash step with PBS, the slides were mounted onto 
microscope slides. Once the mounting media was dry (approximately 30-60 minutes) the 
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slides were stored at -20°C, protected from light, until it was imaged. A complete step by step 
protocol for Immunocytochemistry is included in Appendix G. 
 
2.5.5 Quantification of LC3 and p62 puncta  
 
Images were acquired, as z-stacks (average step-width of 0.8 μm), with the Olympus® Cell^R 
system on an Olympus® IX81 inverted fluorescence microscope (Olympus®, GMBH Japan) 
using the 60X oil immersion objective and the 360 nm and 492 nm excitation filters, using a 
Xenon Arc lamp as excitation source for Hoechst and FITC, respectively A complete step by 
step protocol for image processing is included in Appendix H. 
Prior to quantification, Image z-stacks were pre-processed as follows: Z-stacks were 3D 
deconvoluted with Huygens Professional software (Version 18.10, Scientific Volume Imaging, 
http://svi.nl), using the CMLE algorithm, with a signal to noise ratio (SNR) of 20 and a 
maximum of 40 iterations. 2D maximum intensity projections were produced from 
deconvoluted z-stacks and adaptive Otsu thresholding was applied to each image with a 
threshold smoothing scale of 0.5 and a threshold correction factor of 2.0 (CellProfiler 3.1.5)1. 
LC3 and p62 positive structures were then quantified through particle counts using Fiji (Image 
J) software2. To enhance accuracy of particle counts in each region of interest (ROI), outlines 
were drawn on the original, non-binarized fluorescence images and superimposed over the 
thresholded binary images. 
 
2.6 Statistical Analysis  
 
All controls were normalized using Image Lab software™ and all values were expressed as a 
percentage of the untreated control. Results are presented as mean ± Standard Error of the 
Mean (SEM). Different groups were compared by using one-way analysis of variance 
(ANOVA), followed by a Bonferroni post-hoc test. Graphpad Prism version 5.01 (Graphpad 
Software, Inc, CA, USA) was used to perform statistical analyses. A value of p<0.05 is 
considered to be statistically significant. 
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Chapter 3: Results 
 
3.1 Introduction  
 
The first objective of this study was to identify a concentration of DXR that will induce 
senescence and apoptosis, respectively, in MEFs. A variety of methods were used including: 
MTT assays (cell viability), SA-ß-gal assays and western blots. Secondly, the paracrine of 
effects of fibroblasts were assessed by treating E0771 breast cancer cells with conditioned 
media which was assessed by MTT assays and western blots. The final objective of this study 
was to determine the effects of autophagy inhibition on cancer cell death. These independent 
experiments were carried out to enhance the accuracy and repeatability of the acquired 
results. 
 
3.1.1 Dose response changes in cell viability following DXR treatment 
 
To determine suitable conditions for apoptosis induction in MEFs, an MTT assay was used to 
indirectly measure cell viability. MEFs were treated with 0.1 µM, 0.5 µM, 1 µM, 2 µM, 4 µM, 8 
µM and 10 µM DXR for 24 hours. Based on the dose response experiment, 1 µM to 10 µM 
DXR treatment showed a significant (p<0.001) decrease in cell viability compared to the 
control (Figure 3.1).  
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Figure 3.1: Percentage viability of MEFs after a DXR treatment period determined by an MTT 
assay. MEFs were seeded and treated with different DXR concentrations (0.1 µM, 0.5 µM, 1 µM, 2 µM, 
4 µM, 8 µM and 10 µM) over a period of 24 hours. Results are presented as means ± SEM (n=3). The 
asterisk (*) denotes a significant decrease in cell viability when compared to the control (p<0.001). The 
percentage viable cells after the treatment period were compared with the percentage untreated viable 
cells.  
 
3.1.2 Apoptosis induction in MEFs with DXR 
 
3.1.2.1 Caspase 8 cleavage to determine apoptosis activation 
 
Caspase 8 is situated in the cytosol, in its inactive form (55 kDa) and becomes activated during 
the extrinsic apoptotic pathway (Kominami et al., 2012). Once activated, procaspase 8 is split 
into large (20 kDa) and small (12 kDa) polypeptides (Kruidering & Evan, 2000). Activated 
caspase 8 is then released into the cytosol to cleave downstream effector caspases like 
caspase 3. After the 24-hour treatment with DXR, cleaved caspase 8 expression significantly 
increased in the treatment group (p<0.05) (Figure 3.2). 
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Figure 3.2: Western blot analysis to detect caspase 8 cleavage. MEFs were seeded and treated 
with DXR (1 µM) for 24 hours. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. Caspase 8 expression is shown for 
untreated control MEFs (lanes 1, 3 and 5) and MEFs treated with 1 µM DXR (lanes 2, 4 and 6). Results 
are presented as means ± SEM (n=3). The asterisk (*) denotes a significant increase in cleaved 
caspase 8 expression relative to the control (p<0.05). 
 
3.1.2.2 Caspase 9 cleavage to determine apoptosis activation 
 
Caspase 9 is referred to as an initiator caspase, involved in the intrinsic (mitochondrial) 
apoptotic pathway (Sharifi et al., 2015). The apoptosome activates procaspase 9, which in 
turn stimulates the activation of caspase 3 or caspase 7 to induce apoptosis (Twiddy & Cain, 
2007).  There were no significant changes in caspase 9 expression after DXR treatment 
(p>0.05) and no cleavage was observed (Figure 3.2).  
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Figure 3.3: Western blot analysis to detect caspase 9 cleavage.  MEFs were seeded and treated 
with DXR (1 µM) for 24 hours. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. Caspase 9 expression is shown for 
untreated control MEFs (lanes 1, 3 and 5) and MEFs treated with 1 µM DXR (lanes 2, 4 and 6). Results 
are presented as means ± SEM (n=3). No significant changes were observed in caspase 9 expression 
(p>0.05).  
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3.1.2.3 Caspase 3 cleavage to confirm apoptosis activation  
 
Caspase 3 is activated by both apoptotic pathways (the mitochondrial intrinsic pathway and 
extrinsic death receptor pathway). Caspase 3 is an executioner caspase and only becomes 
active once it is cleaved and activated by initiator caspases after apoptotic signalling. 
Membranes were probed with caspase 3 to determine the ability of DXR to induce apoptosis 
in MEFs. Cleaved caspase 3 significantly increased after the treatment period (p<0.05) (Figure 
3.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Western blot analysis to detect caspase 3 cleavage.  MEFs were seeded and treated 
with DXR (1 µM) for 24 hours. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. Caspase 3 expression is shown for 
untreated control MEFs (lanes 1, 3 and 5) and MEFs treated with 1 µM DXR (lanes 2, 4 and 6). Results 
are presented as means ± SEM (n=3). The asterisk (*) denotes a significant increase in cleaved 
caspase 3 expression relative to the control (p<0.05). 
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3.1.2.4 Poly (ADP-ribose) polymerase cleavage to confirm apoptosis activation  
 
PARP belongs to a family of proteins that is involved in various cellular processes like 
programmed cell death and DNA repair (Herceg and Wang, 2001). To determine the ability of 
DXR to induce apoptosis in MEFs and to confirm the apoptotic results obtained in the caspase 
3 western blots, the expression of PARP was investigated. After the 24-hour treatment period 
with DXR, PARP cleavage decreased significantly relative to the control (p<0.05). Total PARP 
significantly decreased (p<0.05) and the Cleaved/total PARP ratio significantly (p<0.001) 
decreased relative to the control (Figure 3.5). 
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Figure 3.5: Western blot analysis to detect PARP cleavage.  MEFs were seeded and treated with 
DXR (1 µM) for 24 hours. Proteins (50 µg) from MEFs were separated by SDS-PAGE and transferred 
to a PVDF membrane for western blot analysis. PARP expression is shown for untreated control MEFs 
(lanes 1, 3 and 5) and MEFs treated with 1 µM DXR (lanes 2, 4 and 6). Results are presented as means 
± SEM (n=3). The asterisk (*) denotes a significant decrease in total PARP expression relative to the 
control (p<0.05), a significant decrease in cleaved PARP (p<0.001) and a significant decrease in the 
Cleaved/total PARP ratio (p<0.001).  
 
3.2 Determination of senescence in MEFs after DXR treatment 
 
3.2.1 Senescence associated ß-galactosidase assay  
 
Senescence-associated beta-galactosidase is a hydrolase enzyme that catalyses the 
hydrolysis of β-galactosides into monosaccharides in senescent cells. In senescent cells, 
endogenous lysosomal beta-galactosidase is accumulated and overexpressed. When beta-
galactosidase assays are carried out at pH 6.0, cells that are in senescence develop a blue-
coloured stain that results from the cleavage of chromogenic substrate X-gal. MEFs were 
treated with DXR for 4 hours and incubated for 12 days. After the incubation period, the 
number of senescent cells in the fibroblast population was expressed as a percentage relative 
to the number of cells that were not stained. Table 3.1 indicates the average amount of 
senescent cells present in a cell population.  
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Table 3.1: The average amount of senescent cells present in a randomly selected cell population 
(MEFs).  
N1 
Image  Untreated MEFs Total 
cells  
Senescent cells  % 
1 53 23 14 60,87 
2 56 37 21 56,76 
3 50 33 17 51,52 
4 48 29 14 48,28 
5 60 22 11 50,00 
6 56 21 11 52,38 
N2 
Image   Untreated MEFs Total 
cells  
Senescent cells  % 
1 44 23 14 60,87 
2 56 22 11 50,00 
3 53 21 13 61,90 
4 58 21 11 52,38 
5 45 20 10 50,00 
6 52 16 10 62,50 
N3 
Image  Untreated MEFs Total 
cells  
Senescent cells  % 
1 51 29 13 44,83 
2 53 30 20 66,67 
3 45 32 25 78,13 
4 48 31 15 48,39 
5 51 26 16 61,54 
6 52 28 16 57,14 
  
Senescent population: 56,34% 
 
 
Based on the experiment, the average senescent population can be referred to as non-
senescent (population < 80%) (Figure 3.6).  
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Figure 3.6: Phenotypical changes in MEFs following treatment with DXR for senescence 
induction. MEFs were seeded and treated with DXR (2 µM) for 4 hours (a-c). Following the treatment 
period, MEFs were incubated for 12 days in a 5% CO2 incubator at 37°C. MEFs were stained on day 
12 for 16 hours before acquiring the images with a bright field microscope (d-f). 
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3.2.2 Senescence induction in MEFs after DXR treatment  
 
3.2.2.1 Mini chromosome Maintenance Complex Component 2 (MCM2) Expression in 
senescent MEFs   
 
MCM2 is a human nuclear protein that plays an important role in the onset of DNA replication 
and cell division during the cell cycle. Membranes were incubated in MCM2 overnight as an 
indication of the proliferative state of the cells, since senescent cells can no longer proliferate. 
There was a significant (p<0.05) decrease in MCM2 expression on day 8 and 12 when 
compared to the control, as well as when compared to day 1 (p<0.05) (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Western blot analysis to detect MCM2 expression. MEFs were seeded and treated with 
DXR (2 µM) for 4 hours. After treatment, MEFs were incubated in a 5% CO₂ incubator at 37°C for 1, 2, 
4, 8 and 12 days respectively. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. MCM2 expression is shown for untreated 
control MEFs (lane 1) and MEFs treated with 2 µM DXR for 4 hours on Day 1 (lane 2), Day 2 (lane 3), 
Day 4 (lane 4), Day 8 (lane 5) and Day 12 (lane 6). Results are presented as means ± SEM (n=3). The 
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asterisk (*) denotes a significant decrease in MCM2 expression relative to the control (p<0.05) and (#) 
denotes a significant decrease when compared to Day 1 (p<0.05).  
 
3.2.2.2 p53 Expression in senescent MEFs   
 
p53 is a tumour suppressor protein involved in both the apoptotic and cell growth arrest 
(senescence). The expression of p53 was analysed to determine whether DXR induced 
senescence in MEFs. During the treatment periods, ranging from days 1 to 12, p53 expression 
significantly (p<0.05) decreased on day 8 and 12 when compared to day 1. The expression of 
p53 was also significantly decreased (p<0.05) when compared to both the control and day 2 
(Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Western blot analysis to detect p53 expression. MEFs were seeded and treated with 
DXR (2 µM) for 4 hours. After treatment, MEFs were incubated in a 5% CO₂ incubator at 37°C for 1, 2, 
4, 8 and 12 days respectively. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
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transferred to a PVDF membrane for western blot analysis. p53 expression is shown for untreated 
control MEFs (lane 1) and MEFs treated with 2 µM DXR for 4 hours on day 1 (lane 2), day 2 (lane 3), 
day 4 (lane 4), day 8 (lane 5) and day 12 (lane 6). Results are presented as means ± SEM (n=3). The 
asterisk (*) denotes a significant decrease in p53 expression relative to the control (p<0.001); (@) 
denotes a significant decrease relative to Day 1 (p<0.01) and (#) denotes a significant decrease in p53 
expression when compared to Day 2 (p<0.05).  
 
3.2.2.3 p21 Expression in senescent MEFs   
 
p21 is a cyclin-dependent kinase inhibitor that functions as a sensor and effector of many anti-
proliferative signals, thus promoting cell cycle arrest in response to many stimuli. The 
expression of p21 increased significantly (p<0.001) on day 12 when compared to the control. 
p21 expression was also significantly higher on day 12 when compared to day 1, 2, 4 and 8 
(p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Western blot analysis to detect p21 expression. MEFs were seeded and treated with 
DXR (2 µM) for 4 hours. After treatment, MEFs were incubated in a 5% CO₂ incubator at 37°C for 1, 2, 
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4, 8 and 12 days respectively. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. p21 expression is shown for untreated 
control MEFs (lane 1) and MEFs treated with 2 µM DXR for 4 hours on day 1 (lane 2), day 2 (lane 3), 
day 4 (lane 4), day 8 (lane 5) and day 12 (lane 6). Results are presented as means ± SEM (n=3). The 
asterisk (*) denotes a significant increase in p21 expression relative to the control (p<0.001); (#) denotes 
a significant increase relative to day 1, 2, 4 and 8 (p<0.01). 
 
3.2.2.4 p16 Expression in senescent MEFs   
 
p16 contributes to cell cycle regulation by inhibiting the synthesis-phase (S-phase) during the 
cell cycle. p16 binds to CDK4/6 and inhibits CDK4/6-mediated phosphorylation of 
Retinoblastoma (RB) family members.  The expression of p16 significantly (p<0.01) increased 
on day 12 when compared to the control (Figure 3.10). Additionally, p16 expression 
significantly increased (p<0.05) on day 12 when compared to day 1 and day 2. On day 8, p16 
expression was also significantly increased (p<0.05) when compared to the control.  
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Figure 3.10: Western blot analysis to detect p16 expression. MEFs were seeded and treated with 
DXR (2 µM) for 4 hours. After treatment, MEFs were incubated in a 5% CO₂ incubator at 37°C for 1, 2, 
4, 8 and 12 days respectively. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. p16 expression is shown for untreated 
control MEFs (lane 1) and MEFs treated with 2 µM DXR for 4 hours on day 1 (lane 2), day 2 (lane 3), 
day 4 (lane 4), day 8 (lane 5) and day 12 (lane 6). Results are presented as means ± SEM (n=3). The 
asterisk (*) denotes a significant increase in p16 expression relative to the control (p<0.05); (#) denotes 
a significant increase relative to Day 1 (p<0.05) and (@) denotes a significant increase relative to day 
2 (p<0.05).  
 
3.2.2.5 Total Retinoblastoma Expression in senescent MEFs 
 
The Retinoblastoma (RB) protein is known as a tumour suppressor protein that prevents 
excessive cell growth by inhibiting cell cycle progression until the cell is ready to divide. When 
the cell is able to divide, RB is phosphorylated and becomes inactive, allowing the cell cycle 
to continue.  Membranes were probed with RB to confirm cell cycle inhibition. RB expression 
significantly increased (p<0.001) when compared to the control as well as day 1, 2, 4 and 8 
(Figure 3.11).  
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Figure 3.11: Western blot analysis to detect RB expression. MEFs were seeded and treated with 
DXR (2 µM) for 4 hours. After treatment, MEFs were incubated in a 5% CO₂ incubator at 37°C for 1, 2, 
4, 8 and 12 days respectively. Proteins (50 µg) from MEFs were separated by SDS-PAGE and 
transferred to a PVDF membrane for western blot analysis. RB expression is shown for untreated 
control MEFs (lane 1) and MEFs treated with 2 µM DXR for 4 hours on day 1 (lane 2), day 2 (lane 3), 
day 4 (lane 4), day 8 (lane 5) and day 12 (lane 6). Results are presented as means ± SEM (n=3). The 
asterisk (*) denotes a significant increase in RB expression relative to the control as well as day 1, 2, 4 
and 8 (p<0.001). 
 
3.3 Paracrine effects of senescent and apoptotic MEFs on E0771 
cells 
 
E0771 cancer cells were exposed to CM from apoptotic and senescent MEFs to assess the 
effects of paracrine factors released from these cells on breast cancer cells, with or without 
the presence of DXR. Cell viability was indirectly confirmed with an MTT assay and western 
blots were used to determine apoptotic and senescent protein expression. Furthermore, 
autophagy was also inhibited in the E0771 cells with Bafilomycin to determine the effects on 
cell viability.  
 
3.3.1 Changes in cell viability following Conditioned media and DXR treatment  
 
An MTT assay was used to indirectly evaluate cell death when E0771 cells were incubated in 
CM obtained from MEFs. The control CM with added DXR (CM-C-DXR, 1 µM) significantly 
(p<0.001) decreased E0771 cell viability when compared to the control CM (CM-C).  CM 
induced apoptosis with DXR (CM-A-DXR) decreased significantly (p<0.005) from the 
conditioned media apoptosis group (CM-A). CM induced senescence with DXR (CM-S-DXR) 
had a significant increase (p<0.05) when compared to CM-C-DXR and CM-A-DXR (Figure 
3.12).  
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Figure 3.12: Percentage viability of E0771 cells after a conditioned media and DXR treatment 
period determined by an MTT assay. For apoptosis, MEFs were seeded and treated with DXR (1 μM) 
for 24 hours, where after the CM was collected. E0771 cells were incubated with the collected CM while 
the CM-A-DXR group was also treated with DXR (1 µM). For senescence, MEFs were treated with DXR 
(2 µM) for 4 hours, where after the CM was collected during day 7, 10 and 13. E0771 cells were 
incubated in the collected CM (CM-S), while the CM-S-DXR group was also treated with DXR (1µM). 
Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant decrease relative 
to the control (p<0.001); the (@) denotes a significant decrease relative to CM-A (p<0.001) and (#) 
denotes a significant increase in CM-S-DXR relative to CM-C-DXR and CM-A-DXR (p<0.05).   
 
3.3.2 Apoptosis activation in E0771 cells following Conditioned media and DXR 
treatment  
 
3.3.2.1 Caspase 8 cleavage to determine apoptosis in E0771 cells after 
Conditioned media and DXR treatment 
 
Caspase 8 is involved in the intrinsic apoptosis pathway and membranes were therefore 
probed with caspase 8 to determine if the apoptotic pathway was activated after the 24-hour 
treatment period, by determining the amount of cleaved caspase 8 expression. Cleaved 
caspase 8 expression was significantly decreased in the senescence CM treated with DXR 
(CM-S-DXR) when compared to the control group treated with DXR (CM-C-DXR) (p<0.05). 
No significant changes in cleaved caspase 8 were seen in the apoptosis CM (p>0.05). 
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Figure 3.13: Western blot analysis to detect Caspase 8 cleavage in E0771 cells.  E0771 cells were 
seeded and treated with either control, apoptosis or senescence Conditioned media collected from 
MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 
cells were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. 
Caspase 8 expression and cleaved caspase 8 is shown for control CM (lane 1), control CM and DXR 
(lane 2), apoptosis CM (lane 3), apoptosis CM and DXR (lane 4), senescence CM (lane 5) and 
senescence CM and DXR (lane 6). Results are presented as means ± SEM (n=3). For cleaved caspase 
8, the asterisk (*) denotes a significant decrease in CM-S-DXR when compared to CM-C-DXR (p<0.05).  
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3.3.2.2 Caspase 9 cleavage to determine apoptosis in E0771 cells after 
Conditioned media and DXR treatment 
 
Membranes were incubated in caspase 9 primary antibody to determine whether the intrinsic 
or extrinsic apoptosis pathway is involved in E0771 cell death after the treatment period. 
However, no significant changes were observed in caspase 9 expression (p>0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Western blot analysis to detect Caspase 9 cleavage in E0771 cells.  E0771 cells were 
seeded and treated with either control, apoptosis or senescence conditioned media collected from 
MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 
cells were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. 
caspase 9 expression and cleaved caspase 8 is shown for control CM (lane 1), control CM and DXR 
(lane 2), apoptosis CM (lane 3), apoptosis CM and DXR (lane 4), senescence CM (lane 5) and 
senescence CM and DXR (lane 6). Results are presented as means ± SEM (n=3). No significant data 
was observed (p>0.05).  
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3.3.2.3 Caspase 3 to determine apoptosis in E0771 cells after Conditioned media 
and DXR treatment 
 
Caspase 3 is a frequently activated death protease, which catalyses the cleavage of many 
key cellular proteins and interacts with caspase 8 and caspase 9 during programmed cell 
death. Membranes were therefore probed with caspase 3 to determine if apoptosis was 
activated downstream. Furthermore, after the 24-hour treatment period with CM and DXR, 
senescence CM with DXR (CM-S-DXR) was significantly decreased when compared to the 
control DXR group (CM-C-DXR) (p<0.05). No significant changes were seen in the apoptosis 
CM groups (p>0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15: Western blot analysis to detect Caspase 3 in E0771 cells.  E0771 cells were seeded 
and treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 cells 
were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. caspase 
3 expression is shown for control CM (lane 1), control CM and DXR (lane 2), apoptosis CM (lane 3), 
apoptosis CM and DXR (lane 4), senescence CM (lane 5) and senescence CM and DXR (lane 6). 
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Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant decrease in 
caspase 3 expression in CM-S-DXR relative to CM-C-DXR (p<0.05).   
 
3.3.2.4 Poly (ADP-ribose) polymerase cleavage to confirm apoptosis induction 
in E0771 cells after conditioned media and DXR treatment  
 
PARP is involved in programmed cell death and membranes were therefore probed for PARP 
to determine if apoptosis was induced in the E0771 cells after the 24-hour treatment period.  
Total PARP expression significantly decreased in the senescence CM (CM-S) group relative 
to the control CM (CM-C) (p<0.05). There was also a significant decrease in total PARP 
expression in the senescence CM treated with DXR (CM-S-DXR) when compared to control 
CM treated with DXR (CM-C-DXR) (p<0.05). However, no PARP cleavage was observed.  
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Figure 3.16: Western blot analysis to detect PARP cleavage in E0771 cells.  E0771 cells were 
seeded and treated with either control, apoptosis or senescence conditioned media collected from 
MEFs or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 cells were separated 
by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. PARP expression is 
shown for control CM (lane 1), control CM and DXR (lane 2), apoptosis CM (lane 3), apoptosis CM and 
DXR (lane 4), senescence CM (lane 5) and senescence CM and DXR (lane 6). Results are presented 
as means ± SEM (n=3). The asterisk (*) denotes a significant decrease in total PARP expression in 
CM-S relative to the control (CM-C) (p<0.05) and (#) denotes a significant decrease in total PARP 
expression in CM-S-DXR when compared to CM-C-DXR (p<0.05).   
 
3.3.3 Senescence determination in E0771 cells after conditioned media and DXR 
treatment  
 
3.3.3.1 Mini chromosome Maintenance Complex Component 2 (MCM2) 
expression in E0771 cells following treatment  
 
MCM2 plays an important role in the cell cycle regulating DNA replication and the onset of cell 
division. MCM2 expression significantly increased in senescence CM (CM-S) when compared 
to the control (CM-C) (p<0.05). The expression of MCM2 also increased significantly in the 
E0771 cells when treated with senescence CM and 1 µM DXR (CM-S-DXR), when compared 
to the control CM (CM-C) as well as the control CM treated with 1 µM DXR (CM-C and CM-C-
DXR) (p<0.01). No significant changes were observed in apoptosis CM relative to the control 
CM (p>0.05). 
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Figure 3.17: Western blot analysis to detect MCM2 in E0771 cells.  E0771 cells were seeded and 
treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 cells 
were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. MCM2 
expression is shown for control CM (lane 1), control CM and DXR (lane 2), apoptosis CM (lane 3), 
apoptosis CM and DXR (lane 4), senescence CM (lane 5) and senescence CM and DXR (lane 6). 
Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant increase in MCM2 
expression in CM-S-DXR relative to CM-C (p<0.01); (#) denotes a significant increase in MCM 
expression in CM-S relative to the control (CM-C) (p<0.01) and (@) denotes a significant increase in 
CM-S-DXR relative to CM-C-DXR (p<0.05).  
 
3.3.3.2 p53 expression in E0771 cells following treatment  
 
p53 is a tumour suppressor protein and when activated, it induces apoptosis, senescence or 
cell cycle arrest in response to DNA damaging agents or abnormal oncogene transformation. 
The expression of p53 significantly increased in the apoptosis CM treated with DXR (CM-A-
DXR) when compared to the control CM treated with DXR (CM-C-DXR) (p<0.05). No 
significant changes in p53 expression was obtained in the senescence CM relative to the 
control (p>0.05).  
MCM2 
Total Protein  
102 kDa 
Stellenbosch University  https://scholar.sun.ac.za
_________________________________________________________________________________ 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Western blot analysis to detect p53 in E0771 cells.  E0771 cells were seeded and 
treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 cells 
were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. p53 
expression is shown for control CM (lane 1), control CM and DXR (lane 2), apoptosis CM (lane 3), 
apoptosis CM and DXR (lane 4), senescence CM (lane 5) and senescence CM and DXR (lane 6). 
Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant increase in p53 
expression in CM-A-DXR when compared to the CM-C-DXR (p<0.05).  
 
3.3.3.4 p16 expression in E0771 cells following treatment  
 
Expression of p16 maintains Retinoblastoma in a hypo phosphorylated state, which promotes 
the binding to E2F1 and leads to cell cycle arrest at the G1 phase (Serrano, 1997). The 
expression of p16 was significantly increased in the senescence CM treated with DXR (CM-
S-DXR) relative to the control (p<0.05).  
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Figure 3.19: Western blot analysis to detect p16 in E0771 cells.  E0771 cells were seeded and 
treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 cells 
were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. p16 
expression is shown for control CM (lane 1), control CM and DXR (lane 2), apoptosis CM (lane 3), 
apoptosis CM and DXR (lane 4), senescence CM (lane 5) and senescence CM and DXR (lane 6). 
Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant increase in p16 
expression in CM-S-DXR relative to the control (CM-C) (p<0.05)  
 
3.3.3.5 Retinoblastoma expression in E0771 cells following treatment  
 
Senescence induced by p16 acts through the RB pathway be inhibiting the function of CDKs. 
RB then prevents excessive cell growth by inhibiting cell cycle progression. RB expression 
was significantly increased in the senescence CM group treated with 1 µM DXR when 
compared to all the other CM groups, including the CM groups treated with DXR (p<0.05).  
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Figure 3.20: Western blot analysis to detect RB in E0771 cells.  E0771 cells were seeded and 
treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours. Proteins (50 µg) from E0771 cells 
were separated by SDS-PAGE and transferred to a PVDF membrane for western blot analysis. RB 
expression is shown for control CM (lane 1), control CM and DXR (lane 2), apoptosis CM (lane 3), 
apoptosis CM and DXR (lane 4), senescence CM (lane 5) and senescence CM and DXR (lane 6). 
Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant increase in RB 
expression when compared to the CM-C (p<0.05).  
 
3.3.4 Changes in cell viability following conditioned media and DXR treatment 
with autophagy inhibition  
 
An MTT assay was used to indirectly evaluate cell death when E0771 cells are incubated in 
CM for 24 hours obtained from MEFs and autophagy is inhibited. Bafilomycin (400 nM) was 
used to inhibit autophagy four hours prior to the end of the 24-hour treatment period. Cell 
viability significantly decreased when autophagy was inhibited (CM-C-Baf) relative to the 
control CM (p<0.05). A significant decrease in CM-C-DXR and CM-C-DXR-Baf could be seen 
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relative to the control (p<0.001). Once autophagy was inhibited in the CM-C-DXR group, cell 
viability decreased significantly (p<0.05) after 24 hours, which differs from the significant 
increase in cell viability in both apoptosis (CM-A-DXR-BAF vs. CM-A-DXR) and senescence 
(CM-S-DXR-BAF vs. CM-S-DXR) conditioned media treated with 1 µM DXR (p<0.01). 
Autophagy inhibition also significantly increased cell viability in the senescent CM (CM-S vs. 
CM-S-Baf) without the presence of DXR (p<0.001). Furthermore, after the cells were treated 
with DXR, cell viability in the CM-S-DXR group was significantly higher than both the apoptosis 
(CM-A-DXR) and control (CM-C-DXR) group (p<0.05) (Figure 3.21).  
 
 
Figure 3.21: Percentage viability of E0771 cells after conditioned media and DXR treatment 
period with autophagy inhibition determined by an MTT assay. For apoptosis, MEFs were 
seeded and treated with DXR (1 μM) for 24 hours, where after the CM was collected. E0771 cells 
were incubated with the collected CM while the CM-A-DXR group was also treated with DXR (1 µM). 
For senescence, MEFs were treated with DXR (2 µM) for 4 hours, where after the CM was collected 
during day 7, 10 and 13. E0771 cells were incubated in the collected CM (CM-S), while the CM-S-
DXR group was also treated with DXR (1µM). To inhibited autophagy, all the groups were treated with 
Bafilomycin (400 nM) four hours prior to the end of the 24-hour treatment period respectively.   
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Results are presented as means ± SEM (n=3). The asterisk (*) denotes a significant decrease relative 
to the control (p<0.05); the (&) denotes a significant decrease in CM-C-DXR-Baf relative to CM-C-
DXR (p<0.05); the (@) denotes a significant increase in CM-A-DXR-Baf relative to CM-A-DXR 
(p<0.05); (#) denotes a significant increase in CM-S-Baf relative to CM-S (p<0.01) and ($) denotes a 
significant increase in CM-S-DXR-Baf when compared to CM-C-DXR (p<0.05).    
 
3.3.4.1 The expression of LC3 following conditioned media and DXR treatment 
with autophagy inhibition  
 
Microtubule-associated proteins 1A/1B light chain 3B (LC3) is an essential protein involved in 
the autophagic pathway where it is involved in autophagosome biogenesis (Klionsky et al., 
2016). The lipid modified form of LC3 (LC3 II) is involved in autophagosome formation and 
fusion events. The expression of LC3 II was significantly increased in the control CM treated 
with Bafilomycin (CM-C-Baf) relative to the control (CM-C) (p<0.001). Furthermore, LC3 II was 
also increased in the apoptosis CM treated with Bafilomycin when compared to apoptosis CM 
(p<0.05). Similarly, the expression was also increased in senescence CM treated with 
Bafilomycin when compared to senescence CM (CM-S) (p<0.001). However, no significant 
changes in autophagic flux were observed (p>0.05).  
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Figure 3.22: Western blot analysis to detect LC3 II in E0771 cells.  E0771 cells were seeded and 
treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours, alongside with Bafilomycin to inhibit 
autophagy. Proteins (50 µg) from E0771 cells were separated by SDS-PAGE and transferred to a PVDF 
membrane for western blot analysis. LC3 II expression is shown for control CM (lane 1), control CM 
and Baf (lane 2), control CM and DXR (lane 3), control CM, DXR and Baf (lane 4), apoptosis CM (lane 
5), apoptosis CM and Baf (lane 6), apoptosis and DXR (lane 7), apoptosis CM, DXR and Baf (lane 8), 
senescence CM (lane 9), senescence CM and Baf (lane 10), senescence CM and DXR (lane 11) and 
senescence CM, DXR and Baf (lane 12). Images were cropped to represent the different groups in the 
correct order. Results are presented as means ± SEM (n=3). For control and apoptosis CM the 
asterisk (*) denotes a significant decrease in LC3 II expression when compared to the control (p<0.001). 
The (#) denotes a significant decrease in CM-A-Baf relative to CM-C-Baf (p<0.01) and (@) denotes a 
significant decrease in CM-A-DXR-Baf, relative to CM-C-DXR-Baf (p<0.01). For control and 
senescence CM the asterisk (*) denotes a significant increase in LC3 II expression in Cm-C-Baf relative 
to the CM-C (p<0.001) and (@) denotes a significant decrease in CM-S-Baf relative to CM-C-Baf 
(p<0.001).  
 
3.3.4.2 The expression of p62 following conditioned media and DXR treatment 
with autophagy inhibition  
 
The p62 protein, also referred to as sequestome 1 (SQSTM1), is a ubiquitin-binding scaffold 
protein which recognizes cellular toxic waste to be removed by autophagy (Rusten et al., 
2010). The expression of p62 was significantly increased in control CM treated with 
Bafilomycin when compared to the control CM (p<0.05). p62 expression was also significantly 
increased in control CM treated with DXR and Bafilomycin when compared to control CM 
treated with DXR (p<0.01). A significant increase was observed in apoptosis CM treated with 
DXR and Bafilomycin when compared to apoptosis CM treated with DXR (p<0.05). No 
significant changes in senescence CM was observed (p>0.05).  
Stellenbosch University  https://scholar.sun.ac.za
_________________________________________________________________________________ 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 3.23: Western blot analysis to detect p62 in E0771 cells.  E0771 cells were seeded and 
treated with either sontrol, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours, alongside with Bafilomycin to inhibit 
autophagy. Proteins (50 µg) from E0771 cells were separated by SDS-PAGE and transferred to a PVDF 
membrane for western blot analysis. p62 expression is shown for control CM (lane 1), control CM and 
Baf (lane 2), control CM and DXR (lane 3), control CM, DXR and Baf (lane 4), apoptosis CM (lane 5), 
apoptosis CM and Baf (lane 6), apoptosis and DXR (lane 7), apoptosis CM, DXR and Baf (lane 8), 
senescence CM (lane 9), senescence CM and Baf (lane 10), senescence CM and DXR (lane 11) and 
senescence CM, DXR and Baf (lane 12). Images were cropped to represent the different groups in the 
correct order. Results are presented as means ± SEM (n=3). For control and apoptosis CM the 
asterisk (*) denotes a significant increase in p62 expression in CM-C-Baf when compared to the control 
(p<0.05). The (#) denotes a significant increase in CM-C-DXR-Baf relative to CM-C-DXR (p<0.01). For 
control and senescence CM (*) denotes a significant increase in p62 expression in CM-C-Baf relative 
to the control CM (p<0.05).  
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3.3.4.3 The expression of phosphorylated Akt following conditioned media and 
DXR treatment with autophagy inhibition  
 
Akt, or also referred to as Protein kinase B (PKB) is a serine/threonine specific protein kinase 
that is involved in many processes like apoptosis and cellular proliferation. Akt is located in 
the cytosol in its inactive conformation and translocates to the plasma membrane upon 
activation. The interaction between PIP3 and Akt causes a conformational change in Akt which 
exposes the Thr308 and Ser473 phosphorylation sites. Full phosphorylation of Ser473 is 
required for Akt activation (Miao et al., 2010). The expression of phosphorylated Akt (Ser473) 
(pAkt) was significantly increased in both CM-A (compared to CM-A-Baf) and CM-A-DXR 
(compared to CM-A-DXR-Baf) (p<0.001). A significant increase was also observed in CM-S 
when compared to CM-S-Baf (p<0.001). The expression of pAkt (Ser473) was significantly 
decreased in CM-S-DXR-Baf when compared to CM-S-DXR (p<0.05). Furthermore, CM-C 
was significantly decreased when compared to CM-A and CM-S (p<0.001) and CM-C-DXR 
was significantly decreased when compared to CM-A-DXR (p<0.05).  
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Figure 3.24.1: Western blot analysis to detect phosphorylated Akt in E0771 cells.  E0771 cells 
were seeded and treated with either control, apoptosis or senescence conditioned media collected from 
MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours, alongside with Bafilomycin 
to inhibit autophagy. Proteins (50 µg) from E0771 cells were separated by SDS-PAGE and transferred 
to a PVDF membrane for western blot analysis. pAkt expression is shown for control CM (lane 1), 
control CM and Baf (lane 2), control CM and DXR (lane 3), control CM, DXR and Baf (lane 4), apoptosis 
CM (lane 5), apoptosis CM and Baf (lane 6), apoptosis and DXR (lane 7), apoptosis CM, DXR and Baf 
(lane 8), senescence CM (lane 9), senescence CM and Baf (lane 10), senescence CM and DXR (lane 
11) and senescence CM, DXR and Baf (lane 12). Images were cropped to represent the different groups 
in the correct order. Results are presented as means ± SEM (n=3). For control and apoptosis CM the 
asterisk (*) denotes a significant decrease in CM-C relative to CM-A (p<0.001), ($) denotes a significant 
decrease in CM-C-DXR relative to CM-A-DXR (p<0.001) and the (#) denotes a significant increase in 
CM-A and CM-A-DXR relative to the Baf groups (p<0.001). For control and senescence CM ($) 
denotes a significant decrease in CM-C-Baf relative to CM-S-Baf (p<0.01) and (@) denotes a significant 
increase in CM-S (p<0.001) and CM-S-DXR (p<0.05) relative to the Baf groups.  
 
3.3.4.4 The expression of total Akt following conditioned media and DXR 
treatment with autophagy inhibition  
 
The expression of total Akt was significantly increased in control CM treated with DXR and 
Bafilomycin (CM-C-DXR-Baf) when compared to control CM treated with DXR (CM-C-DXR) 
(p<0.01) and the expression was also increased in apoptosis CM treated with DXR and 
Bafilomycin (CM-A-DXR-Baf) when compared to apoptosis CM treated with DXR (CM-A-DXR) 
(p<0.01). Senescence CM treated with DXR and Bafilomycin (CM-S-DXR-Baf) was also 
significantly increased when compared to CM-S-DXR (p<0.05). Furthermore, Akt was 
significantly decreased in both CM-S and CM-A relative to control CM (p<0.05).  
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Figure 3.24.2: Western blot analysis to detect total Akt in E0771 cells.  E0771 cells were seeded 
and treated with either control, apoptosis or senescence conditioned media collected from MEFs as 
described earlier or treated with CM and 1 µM DXR for 24 hours, alongside with Bafilomycin to inhibit 
autophagy. Proteins (50 µg) from E0771 cells were separated by SDS-PAGE and transferred to a PVDF 
membrane for western blot analysis. Total Akt expression is shown for control CM (lane 1), control CM 
and Baf (lane 2), control CM and DXR (lane 3), control CM, DXR and Baf (lane 4), apoptosis CM (lane 
5), apoptosis CM and Baf (lane 6), apoptosis and DXR (lane 7), apoptosis CM, DXR and Baf (lane 8), 
senescence CM (lane 9), senescence CM and Baf (lane 10), senescence CM and DXR (lane 11) and 
senescence CM, DXR and Baf (lane 12). Images were cropped to represent the different groups in the 
correct order. Results are presented as means ± SEM (n=3). For control and apoptosis CM the 
asterisk (*) denotes a significant decrease in CM-C-DXR when compared to CM-C (p<0.01) and ($) 
denotes a significant increase in CM-C-DXR-Baf when compared to CM-C-DXR (p<0.01). The (#) 
denotes a significant decrease in CM-A relative to CM-C (p<0.05) and (@) denotes a significant 
decrease in CM-A-DXR when compared to CM-A-DXR-Baf (p<0.01). For control and senescence CM 
(*) denotes a significant decrease in CM-S and CM-C-DXR relative to CM-C (p<0.01) and (@) denotes 
a significant increase in Akt in CM-S-DXR-Baf relative to CM-S-DXR (p<0.05).  
 
The ratio of phosphorylated Akt to total Akt was then calculated and used as a proliferative 
indicator. The expression of pAkt/Total Akt was significantly increased in apoptosis CM treated 
with DXR (CM-A-DXR) (p<0.001) as well as in senescence CM (CM-S) (p<0.001) and 
senescence CM treated with DXR (CM-S-DXR) (p<0.05). Furthermore, the expression on 
pAkt/total Akt was also significantly increased in the apoptosis and senescence CM when 
compared to the control CM (p<0.05).  
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Figure 3.24.3: pAkt/total Akt in E0771 cells. The ratio between phosphorylated Akt and total Akt was 
determined. For control and apoptosis CM the asterisk (*) denotes a significant decrease in CM-C-
DXR when compared to CM-A-DXR (p<0.001), (#) denotes a significant decrease in CM-C when 
compared to CM-A (p<0.05). The (@) denotes a significant decrease in CM-A-Baf relative to CM-A 
(p<0.05) and ($) denotes a significant increase in CM-A-DXR (p<0.001). For control and senescence 
CM (*) denotes a significant decrease in CM-C when compared to CM-S (p<0.001), (@) denotes a 
significant increase in CM-S relative to CM-S-Baf (p<0.001) and (#) denotes a significant increase in 
CM-S-DXR relative to CM-S-DXR-Baf (p<0.05).   
 
3.3.4.5 The expression of phosphorylated ERK following conditioned media and 
DXR treatment with autophagy inhibition  
 
The MAPK/ERK pathway (also referred to as the Ras-Raf-MEK-ERK pathway) transports 
signals from a cell surface receptor towards DNA in the cellular nucleus to activate processes 
like cell division, proliferation, differentiation and survival. Once ERK1/2 is phosphorylated by 
MEK1/2, it becomes activated and is translocated to the nucleus. Phosphorylated ERK1 
(pERK 1) was significantly decreased in the control CM treated with Bafilomycin (CM-C-Baf) 
when compared to the control CM (CM-C) (p<0.05). No significant changes in the apoptosis 
CM were observed (p<0.05). For senescence CM, pERK 1 was significantly increased in 
senescence CM treated with DXR and Bafilomycin (CM-S-DXR-Baf) when compared to 
senescence CM treated with Bafilomycin (CM-S-Baf) as well as control CM treated with DXR 
and Bafilomycin (CM-C-DXR-Baf) (p<0.001). Additionally, control CM treated with Bafilomycin 
(CM-C-Baf) and control CM treated with DXR and Baf (CM-C-DXR-Baf) was significantly 
decreased relative to the control (p<0.05).  
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For phosphorylated ERK 2 (pERK 2), apoptosis CM treated with DXR (CM-A-DXR) was 
significantly increased when compared to apoptosis CM (CM-A), control CM treated with DXR 
(CM-C-DXR) as well as apoptosis CM treated with DXR and Bafilomycin (CM-A-DXR-Baf) 
(p<0.001). The expression of pERK 2 was also significantly increased in apoptosis CM treated 
with Bafilomycin (CM-A-Baf) when compared to the control treated with Bafilomycin (CM-C-
Baf) (p<0.05). Additionally, pERK 2 was significantly increased in senescence CM treated with 
Bafilomycin (CM-S-Baf) when compared to senescence CM (CM-S) as well as the control 
groups (p<0.001). The expression was also increased in senescence CM treated with DXR 
and Bafilomycin (CM-S-DXR-Baf) relative to senescence CM treated with DXR (CM-S-DXR) 
(p<0.01). 
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Figure 3.25.1: Western blot analysis to detect phosphorylated ERK in E0771 cells.  E0771 cells 
were seeded and treated with either control, apoptosis or senescence conditioned media collected from 
MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours, alongside with Bafilomycin 
to inhibit autophagy. Proteins (50 µg) from E0771 cells were separated by SDS-PAGE and transferred 
to a PVDF membrane for western blot analysis. Results are presented as means ± SEM (n=3). pERK1/2 
expression is shown for control CM (lane 1), control CM and Baf (lane 2), control CM and DXR (lane 
3), control CM, DXR and Baf (lane 4), apoptosis CM (lane 5), apoptosis CM and Baf (lane 6), apoptosis 
and DXR (lane 7), apoptosis CM, DXR and Baf (lane 8), senescence CM (lane 9), senescence CM and 
Baf (lane 10), senescence CM and DXR (lane 11) and senescence CM, DXR and Baf (lane 12). pERK 
1: For control and apoptosis CM the asterisk (*) denotes a significant decrease in CM-C-Baf when 
compared to CM-C (p<0.05). For control and senescence CM (*) denotes a significant decrease in 
CM-C-Baf and CM-C-DXR-Baf relative to the control (p<0.05). The (#) denotes a significant decrease 
in CM-C-DXR-Baf when compared to CM-S-DXR-Baf (p<0.001) and (@) denotes a significant increase 
in CM-S-DXR-Baf relative to CM-S-DXR (p<0.001). pERK 2: For control and apoptosis CM the 
asterisk (*) denotes a significant increase in CM-A-Baf relative to CM-C-Baf (p<0.05), (#) denotes a 
significant decrease in CM-C-DXR relative to CM-A-DXR (p<0.001) and (@) denotes a significant 
increase in CM-A-DXR relative to CM-A-DXR-Baf (p<0.001). For control and senescence CM (#) 
denotes a significant decrease in CM-C-DXR relative to CM-S-DXR (p<0.05), (@) denotes a significant 
decrease in CM-C-DXR-Baf relative to CM-S-DXR-Baf (p<0.001); ($) denotes a significant increase in 
CM-S-Baf (p<0.001) and (*) denotes a significant decrease in CM-S-DXR relative to CM-S-DXR-Baf 
(p<0.01).  
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3.3.4.6 The expression of total ERK 1 and ERK 2 following conditioned media 
and DXR treatment with autophagy inhibition 
 
For apoptosis, total ERK 1 was significantly increased in CM-C-DXR-Baf when compared to 
all control CM groups (p<0.001). The expression of total ERK1 was significantly increased in 
apoptosis CM (CM-A) when compared to control CM (CM-C) (p<0.05) and was also increased 
in apoptosis CM treated with DXR and Bafilomycin (CM-A-DXR-Baf) when compared to 
apoptosis CM treated with DXR (CM-A-DXR) (p<0.05). For senescence, total ERK 1 
expression was significantly increased in senescence CM treated with Bafilomycin (CM-S-Baf) 
when compared to control CM treated with Baf (CM-C-Baf) (p<0.001) and the expression was 
also increased in senescence CM treated with DXR and Bafilomycin (CM-S-DXR-Baf) when 
compared to senescence CM treated with DXR (CM-S-DXR) (p<0.01).  
 
For apoptosis, the expression of total ERK 2 was significantly increased in control CM treated 
with DXR and Bafilomycin (CM-C-DXR-Baf) relative to the control (p<0.01). It was also 
increased in apoptosis CM treated with Bafilomycin (CM-A-Baf) when compared to apoptosis 
CM (CM-A) (p<0.05) and was also increased in CM-A-Baf relative to the control treated with 
Bafilomycin (CM-C-Baf) (p<0.05). For senescence, CM treated with Bafilomycin (CM-S-Baf) 
was significantly increased when compared to CM-S as well as control CM treated with 
Bafilomycin (p<0.01). The expression of total ERK 2 was also increased in senescence CM 
treated with DXR (CM-S-DXR) (p<0.05).  
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Figure 3.25.2: Western blot analysis to detect total ERK 1 and ERK 2 in E0771 cells.  E0771 cells 
were seeded and treated with either control, apoptosis or senescence conditioned media collected from 
MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours, alongside with Bafilomycin 
to inhibit autophagy. Proteins (50 µg) from E0771 cells were separated by SDS-PAGE and transferred 
to a PVDF membrane for western blot analysis. Results are presented as means ± SEM (n=3). ERK 
expression is shown for control CM (lane 1), control CM and Baf (lane 2), control CM and DXR (lane 
3), control CM, DXR and Baf (lane 4), apoptosis CM (lane 5), apoptosis CM and Baf (lane 6), apoptosis 
and DXR (lane 7), apoptosis CM, DXR and Baf (lane 8), senescence CM (lane 9), senescence CM and 
Baf (lane 10), senescence CM and DXR (lane 11) and senescence CM, DXR and Baf (lane 12). ERK 
1: For control and apoptosis CM the asterisk (*) denotes a significant increase in CM-C-DXR-Baf 
when compared to CM-C (p<0.05), (#) denotes a significant decrease in CM-C-DXR relative to CM-A-
DXR (p<0.001) and (@) denotes a significant increase in CM-A-DXR-Baf relative to CM-A-DXR 
(p<0.001). For control and senescence CM (*) denotes a significant decrease in CM-C-DXR-Baf 
(p<0.01), the (#) denotes a significant increase in CM-S-Baf relative to CM-C-Baf (p<0.001) and (@) 
denotes a significant increase in CM-S-DXR-Baf relative to CM-S-DXR (p<0.001). ERK 2: For control 
and apoptosis CM the asterisk (*) denotes a significant increase in CM-C-DXR-Baf relative to CM-C 
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(p<0.01), (@) denotes a significant decrease in CM-C-Baf relative to CM-A-Baf (p<0.05) and (#) 
denotes a significant increase in CM-A-Baf relative to CM-A (p<0.001). For control and senescence 
CM (#) denotes a significant decrease in CM-C-Baf relative to CM-S-Baf (p<0.001), (*) denotes a 
significant increase in CM-S-DXR-Baf relative to the control (p<0.01); (@) denotes a significant increase 
in CM-S-Baf relative to CM-S (p<0.01) and ($) denotes a significant increase in CM-S-DXR relative to 
CM-C-DXR (p<0.05).  
 
The ratio of phosphorylated ERK 1 and total ERK 1 was then determined. For apoptosis, the 
expression of pERK1/total ERK1 was significantly decreased (p<0.01) in all apoptosis CM 
groups, relative to the control (CM-C). The expression was also decreased in control CM 
treated with DXR and Bafilomycin when compared to control CM treated only with DXR 
(p<0.01). Furthermore, the expression of pERK 1/total ERK 1 was also significantly decreased 
in apoptosis CM treated with DXR when compared to the control CM treated with DXR 
(p<0.05). For senescence, the expression was significantly decreased in all senescence CM 
groups, except CM-S-DXR-Baf (p<0.01). Additionally, senescence CM treated with DXR and 
Bafilomycin (CM-S-DXR-Baf) was significantly increased when compared to the control CM 
treated with DXR and Bafilomycin (CM-C-DXR-Baf) (p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25.3: pERK 1/total ERK 1 in E0771 cells. The ratio of phosphorylated ERK 1 and total ERK 
1 was determined. For control and apoptosis CM (*) denotes a significant decrease in CM-C-DXR-
Baf (p<0.001) and all apoptosis CM (p<0.01); (#) denotes a decrease in CM-C-DXR-Baf when 
compared to CM-C-DXR (p<0.01) and (@) denotes a decrease in CM-A-DXR when compared to CM-
C-DXR (p<0.05). For control and senescence CM (*) denotes a significant decrease in CM-C-DXR-
Baf (p<0.001) and in CM-S, CM-S-Baf and CM-C-DXR relative to the control (p<0.01); (#) denotes a 
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decrease in CM-C-DXR-Baf when compared to CM-C-DXR (p<0.01) and (@) denotes an increase in 
CM-S-DXR-Baf when compared to CM-C-DXR-Baf (p<0.05).  
 
The ratio for phosphorylated ERK 2 and total ERK 2 was also determined. For apoptosis, the 
expression of pERK 2/total ERK 2 was significantly increased in apoptosis CM treated with 
DXR (CM-A-DXR) relative to the control (p<0.01) and apoptosis CM (p<0.01). Apoptosis CM 
treated with DXR and Bafilomycin (CM-A-DXR-Baf) was also significantly decreased when 
compared to senescence CM treated with DXR (CM-S-DXR) (p<0.01). For senescence, the 
expression was significantly increased in senescence CM treated with DXR (CM-S-DXR) 
(p<0.001) and senescence CM treated with DXR and Bafilomycin (CM-S-DXR-Baf) (p<0.05) 
relative to the control as well as senescence CM (CM-S) (p<0.001 and p<0.01).  
 
 
 
 
 
 
 
 
 
Figure 3.25.4: pERK 2/total ERK 2 in E0771 cells. The ratio of phosphorylated ERK 2 and total ERK 
2 was determined. For control and apoptosis CM (*) denotes a significant increase in CM-A-DXR 
relative to CM-C (p<0.01); (#) denotes a decrease in CM-C-DXR-Baf when compared to CM-C-DXR 
(p<0.01) and (@) denotes a decrease in CM-A when compared to CM-C-DXR (p<0.01). For control 
and senescence CM (*) denotes a significant increase in CM-S-DXR-Baf (p<0.05) and CM-S-DXR 
(p<0.001) relative to the control; ($) denotes an increase in CM-S-DXR (p<0.001) and CM-S-DXR-Baf 
(p<0.01) when compared to CM-S; (#) denotes a decrease in CM-C-DXR-Baf when compared to CM-
S-DXR-Baf (p<0.05) and (@) denotes a significant decrease in CM-C-DXR when compared to CM-S-
DXR (p<0.01).  
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3.4 Autophagy Immunocytochemistry: Quantification of LC3 and 
p62 puncta 
 
3.4.1 LC3 II stain following conditioned media and DXR treatment with 
autophagy inhibition 
 
An Immunocytochemistry stain was used to confirm the results obtained from the LC3 western 
blot expression. For apoptosis, all groups were significantly increased when compared to the 
control (p<0.001). The expression of LC3 was also increased in the control CM treated with 
DXR and Bafilomycin when compared to control CM treated with DXR (p<0.05). For 
senescence, the control CM treated with DXR as well as DXR and Bafilomycin was 
significantly increased when compared to the control (p<0.01 and p<0.001). Furthermore, LC3 
was significantly decreased in senescence CM treated with DXR and Bafilomycin when 
compared to the control CM treated with DXR and Bafilomycin (p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.26.1: Immunocytochemistry analysis of LC3 expression in E0771 cells. E0771 cells were 
seeded onto coverslips and treated with either control, apoptosis or senescence conditioned media 
collected from MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours, alongside 
with Bafilomycin to inhibit autophagy. The cells were fixed and LC3 primary antibody was added, 
followed by overnight incubation. After incubation with secondary antibody, the cells were imaged. 
Results are presented as means ± SEM (n=3). For control and apoptosis CM, the asterisk (*) denotes 
a significant increase relative to the control (p<0.01 and p<0.001) and (#) denotes a significant increase 
relative to CM-C-DXR (p<0.05). For control and senescence CM, (*) denotes a significant increase 
relative to the control (p<0.01 and p<0.001); (#) denotes a significant increase relative to CM-C-DXR 
(p<0.05) and (@) denotes a significant decrease relative to CM-C-DXR-Baf (p<0.05). 
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3.4.1.1 Representative images for LC3 puncta quantification  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Control unprocessed b) Control deconvolution 
c) CM-C d) CM-C-Baf 
e) CM-C-DXR f) CM-C-DXR-Baf 
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i) CM-A-DXR j) CM-A-DXR-Baf 
k) CM-S l) CM-S-Baf 
g) CM-A h) CM-A-Baf 
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Figure 3.26.1.1: Representative images of LC3 puncta in E0771 cells following CM and DXR 
treatment and autophagy inhibition. E0771 cells were seeded and treated with control CM (as 
previously described) and DXR for 24 hours and Bafilomycin was added 4 hours prior to the staining 
protocol (c-f). The same protocol was followed for apoptosis CM (g-j) and senescence CM (k-n).  
 
3.4.2 p62 stain following conditioned media and Doxorubicin treatment with 
autophagy inhibition 
 
An Immunocytochemistry stain was used to confirm the results obtained from the p62 western 
blot expression. For apoptosis, all apoptosis CM and control CM treatment groups were 
significantly increased when compared to the control (p<0.001). The expression of p62 was 
also increased in all senescence CM treatment groups when compared to senescence CM 
(p<0.001). For senescence, the control CM treated with DXR as well as DXR and Bafilomycin 
and senescence CM treated with DXR as well as DXR and Bafilomycin was significantly 
increased when compared to the control (p<0.001 and p<0.01). Furthermore, p62 was 
significantly increased in senescence CM treated with DXR as well as DXR and Bafilomycin 
when compared to senescence CM (p<0.001).  
m) CM-S-DXR n) CM-S-DXR-Baf 
Stellenbosch University  https://scholar.sun.ac.za
_________________________________________________________________________________ 
90 
 
 
 
 
 
 
 
 
Figure 3.26.2: Immunocytochemistry analysis of p62 expression in E0771 cells. E0771 cells were 
seeded onto coverslips and treated with either control, apoptosis or senescence conditioned media 
collected from MEFs as described earlier or treated with CM and 1 µM DXR for 24 hours, alongside 
with Bafilomycin to inhibit autophagy. The cells were fixed and p62 primary antibody was added, 
followed by overnight incubation. After incubation with secondary antibody, the cells were imaged. 
Results are presented as means ± SEM (n=3). For control and apoptosis CM, the asterisk (*) denotes 
a significant increase relative to the control (p<0.001) and (#) denotes a significant increase relative to 
CM-S (p<0.001). For control and senescence CM, (*) denotes a significant increase relative to the 
control (p<0.01 and p<0.001) and (#) denotes a significant increase relative to CM-S (p<0.001). 
 
3.4.2.1 Representative images for p62 puncta quantification  
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c) CM-C-DXR d) CM-C-DXR-Baf 
e) CM-A f) CM-A-Baf 
g) CM-A-DXR h) CM-A-DXR-Baf 
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Figure 3.26.2.1: Representative images of p62 puncta in E0771 cells following CM and DXR 
treatment and autophagy inhibition. E0771 cells were seeded and treated with control CM (as 
previously described) and DXR for 24 hours and Bafilomycin was added 4 hours prior to the staining 
protocol (a-d). The same protocol was followed for apoptosis CM (e-h) and senescence CM (i-l).  
 
 
 
 
 
 
 
i) CM-S j) CM-S-Baf 
k) CM-S-DXR 
l) CM-S-DXR-Baf k) CM-S-DXR 
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Chapter 4  
 
4. Discussion  
 
The most common cancer among women in both developed and developing countries is 
breast cancer and many treatment strategies are therefore being developed to reduce 
oncogenic transformation. (Desantis et al., 2016). A major treatment strategy currently used 
worldwide is chemotherapeutic drugs, such as DXR. These chemotherapeutic drugs function 
by damaging DNA, which has an influence on the cell’s ability to divide.  In response to the 
DNA damage, cancer cells can undergo apoptosis or senescence, depending on the dosage 
(Amornsupak et al., 2014). Cancer cells proliferate at faster rates than normal cells in the 
environment, which makes them more susceptible to apoptosis induced by these drugs 
(Vasillev et al., 2017). However, lower dosages or concentrations of DXR also target normal 
cells in the tumour microenvironment and these cells often induce a senescent state. These 
senescent cells actively communicate with neighbouring cells and the tumour 
microenvironment (TME), through the secretion of molecules that constitute the senescence 
associated secretory phenotype (SASP) such as cytokines, chemokines, and growth factors 
(Coppé et al., 2014). Senescent fibroblasts in the TME could therefore secrete certain factors 
that could promote the transformation and proliferation of cancer cells. The aim of this study 
was therefore to assess the effects of conditioned media harvested from senescent and 
apoptotic fibroblasts on breast cancer cells and to determine whether autophagy inhibition 
contributes to treatment resistance in cancer cells. 
 
4.1 Induction of apoptosis in MEFs 
 
4.1.1 Cell viability 
 
An MTT assay was used to assess the cell viability of MEFs following a 24-hour treatment with 
DXR. In MEFs, 1 µM to 10 µM DXR significantly decreased cell viability after the 24-hour 
treatment (Figure 3.1).  
No significant differences in cell viability were detected when MEFs were treated with dosages 
lower than 1 µM. This agrees with previous studies which showed that MEFs treated with 0.2 
µg/ml DXR for 17 to 18 hours failed to undergo apoptosis (Attardi et al., 2000). The data is 
also supported by the study of Park et al, where the authors treated MEFs with DXR ranging 
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between 1 and 8 µM, for 24 hours. 1 µM and 2 µM DXR significantly decreased cell viability. 
Higher concentrations of DXR had no significant effects (Park et al., 2012). 
 
4.1.2 Markers of apoptosis  
 
Western blot analyses were used to indicate whether apoptosis occurred in MEFs 24 hours 
after DXR treatment. DXR is often associated with ROS production, which plays an important 
part in caspase activation to serve as primary mediators for the apoptosis pathway. Cleaved 
caspase 3 is used as a central marker to indicate if the caspase cascade has been activated 
and follows activation of either the extrinsic pathway (caspase 8) or the intrinsic mitochondrial 
pathway (caspase 9) (Wei et al., 2000).  
Total Caspase 8 expression significantly decreased and cleaved caspase 8 significantly 
increased in the DXR treated MEFs when compared to the control. Similar results were 
obtained by Wei et al who treated MEFs with 3 µM of DXR and found increased levels of 
caspase 8 cleavage in the DXR treated cells. The authors also concluded that higher 
concentrations of DXR (5 µM to 10 µM) can further increase the activation of caspase 8 in 
these cells.  
No significant changes in expression of cleaved caspase 9 was observed after the 24-hour 
treatment period. Contradictory to our findings however, Kuida et al concluded that embryonic 
fibroblasts from caspase 9-null mice are resistant to apoptosis induced by DNA damaging 
agents. The authors therefore concluded that the activation and cleavage of caspase 9 is an 
important mechanism for apoptosis induction. Based on the current study, 1 µM of DXR only 
activated the extrinsic pathway efficiently in MEFs, by activating caspase 8 to recruit pro-
caspase 3 or 7 to induce apoptosis. 
We have further demonstrated a decrease in total caspase 3 expression and a significant 
increase in cleaved caspase 3 following 24-hour treatment with 1 µM DXR (Figure 3.4). These 
results are supported by the work of Weigh et al, who found that there is a time frame between 
8 and 12 hours for DXR to induce caspase activation in MEFs, when MEFs are treated with 3 
µM DXR.  
The significant increase in caspase 3 activation and cleavage was however not supported by 
an increase in PARP activation and cleavage. Instead, PARP activation and cleavage 
significantly decreased after 24-hour DXR treatment (Figure 3.5). This finding was unexpected 
since Caspase 3 cleavage normally induces PARP activation and cleavage (Munoz-Gamez 
et al., 2005). These results also contradict the findings of Munoz-Gamez et al, who indicated 
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that after caspase 3 activation, there was a significant increase in PARP cleavage (Munoz-
Gamez et al., 2005). The differences in the obtained results could possibly be based on 
treatment duration. The above-mentioned authors assessed PARP cleavage after a 72-hour 
treatment period. It could therefore be possible that the 24-hour treatment period is not 
substantial enough to induce PARP cleavage specifically in MEFs.  
In response to genotoxic stress and DNA damage, p53 is rapidly increased in MEFs. This 
occurrence led Ding et al to suggest that when p53 is activated, it is able to recruit the 
assembly of a caspase 8 activating process by inducing protein-protein interactions in the cell. 
Caspase 8 would therefore be able to target caspase 9 through proteolysis, to activate 
caspase 3 and induce apoptosis (Ding et al., 2000).   
In summary, these results support the idea that more than one mechanism is able to induce 
programmed cell death and that these mechanisms are highly dependent on the death 
stimulus as well as the cell type being investigated.  
 
4.2 Induction of senescence in MEFs 
 
4.2.1 Senescence associated ß-galactosidase activity  
 
A SA-ß-gal assay was performed to measure endogenous lysosomal beta-galactosidase 
activity in senescent MEFs. MEFs were treated with 2 µM DXR for 4 hours (Figure 3.6). After 
the treatment period, MEFs were incubated for 12 days before the stain was clearly visible. 
The number of senescent cells (whole cells that were stained bright blue) was then compared 
to the total number of cells in the cell population. A cell population is considered to be 
senescent when 80% of the population is positively stained. However, based on the results 
obtained from different sample areas of the cell population, we were unable to refer to the 
population as being senescent. The results do however show that DXR is capable of inducing 
senescence in a large portion of the cell population. The findings of Ghosh and co-workers 
support the ability of DXR to induce senescence in MEFs. The authors used a DXR treatment 
period of four days and found an increase in the number of SA-ß-gal positive cells in fibroblasts 
and endothelial cells (Ghosh et al., 2016). The findings of Ghosh et al was however significant, 
but this could indicate that treatment duration is a main determinant in whether or not 
senescence will be induced in most of the cell population. However, Te Poele and colleagues 
obtained contradicting results. An increase in SA-ß-gal staining was observed in 41% of breast 
tumours after DXR treatment, but the stain was confined to tumour cells and no detection in 
normal tissue was present (te Poele et al., 2002). These contradictory findings therefore 
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highlight the importance of optimizing senescence induction for different cell lines. DXR 
therefore has the ability to induce senescence in many cells, including cancerous and non-
cancerous cell lines.  
 
4.2.2 Markers of senescence  
 
MCM2 is part of the mini chromosome maintenance protein complex and plays an important 
role in DNA replication and cell proliferation (Lei, 2005). Once senescence is induced in cells, 
the cells are unable to proliferate. The expression of MCM2 was therefore used to assess the 
proliferative capacity of MEFs after DXR treatment. Following treatment with 2 µM DXR for 4 
hours, MEFs were incubated for different time periods (day 1, 2, 4, 8 and 12). There was a 
significant decrease in MCM2 expression on day 8 and 12 when compared to both the control 
and day 1 groups (Figure 3.7). Based on this finding, it can be concluded that the MEFs had 
lost their ability to proliferate after the treatment period. Chen et al subjected normal human 
fibroblasts to oxidative stress (can also be induced by DXR) by treating the cells with hydrogen 
peroxide for 2 hours. Similarly, to our findings, MCM2 expression significantly decreased in 
the near replicative senescent cells and was undetectable in the fully senescent cells (Chen 
et al., 2004).  
The expression of p53 was increased on day 1 after the DXR treatment when compared to 
the control and then significantly decreased on day 8 and 12 when compared to both the 
control and day 1 groups. DNA damage induces the expression and activation of p53 and 
often results in the rapid accumulation thereof (Gire and Dulic, 2015). The tumour suppression 
functions of p53 are specifically linked with the activation of downstream targets to induce 
senescence or cell cycle arrest (Qian and Chen, 2013). Senescent cells are generally also 
characterized by the enhanced expression of p53 targets, like p21, a mediator of senescence. 
p53 therefore targets and activates p21 to induce senescence and this could possibly explain 
why there was an initial increase in p53 expression, followed by a significant decrease on day 
8 and 12 (Figure 3.8). Furthermore, these results are also supported by a significant increase 
in p21 expression on day 12 (Figure 3.9), which possibly indicates that p53 tumour 
suppression functioning was reduced by p21. Several studies support these findings. Wang 
et al observed that when wild type MEFs are treated with 0.5 µM and 1 µM DXR, p21 
accumulation is significantly enhanced (Wang et al., 2012). Upon DNA damage, p53 levels in 
the cell are increased, which eventually causes an increase in p21 expression. p21 binds to 
and inhibits CDK, causing cell cycle arrest in the G1 phase. Attardi et al treated wild type MEFs 
with various DNA damaging agents, including DXR. Their results indicated that high levels of 
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p53 expression was associated with low levels of p21. However, in p53 -/- MEFs, no changes 
in p21 expression was observed and cell cycle arrest could not be induced (Attari et al, 2004).  
The overexpression of p16 has been reported in senescent fibroblasts in response to DNA 
damage and oxidative stress (Wu et al., 2007). DXR treatment gradually increased the 
expression of p16 from day 2 to day 12.  On day 12, p16 expression was significantly increased 
when compared to the control (Figure 3.10). These findings are similar to those made by 
Spallarossa et al. The authors indicated that once endothelial progenitor cells (EPCs) are 
treated with 0.25 µM DXR, p16 levels increased in SA-ß-gal positive cells (Spallarossa et al., 
2010). Additionally, Demaria and authors exposed MEFs to different concentrations of DXR 
to determine cell proliferation inhibition. Growth arrest was seen at 250 nM DXR treatment. 
Senescence was also confirmed by the increase in p16 expression in cells as well as 
components of the SASP (IL-1α and IL-6) (Demaria et al., 2017). 
The Retinoblastoma (RB) protein is a vital tumour suppressor that blocks the progression of 
the cell cycle by inhibiting E2F transcription. RB expression was significantly increased on day 
12 (Figure 3.11). Jackson et al indicated that after DNA damage occurs (induced by 1 µM 
DXR), p130 levels (an RB family member) are elevated in MEFs after 24 hours of treatment 
(Jackson et al., 2006). He and co-workers exposed mouse embryonic stem cells to low doses 
of DXR (50 nM) for 48 hours. Similarly, RB expression was significantly increased after the 
treatment period (He et al., 2016). Further findings indicated that in response to DXR, RB 
expression was not significantly increased in p53 knock down cells. This data could possibly 
indicate that p53 mediated regulation of the RB protein occurs at the post-transcriptional level.  
The markers of senescence influence each other during the senescence pathway. The 
expression of MCM2 decreased after treatment, which indicates that the MEFs started to lose 
their ability to proliferate, which supports the idea that senescent cells do not continue to grow. 
The p53, p21, p16 and RB proteins are tumour suppressor proteins that have the ability to 
block cell growth and induce senescence, and it was thus expected that the expression of 
these markers would increase. The SA-ß-gal assay revealed that not all the MEFs in the cell 
population were senescent, which could have contributed to the results obtained for the 
senescence markers. If a larger proportion of the population were senescent, significant 
changes in the expression of p53 might have been observed, and possibly also at earlier time 
points for p16 and p21.   
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4.3 The paracrine effects of senescent and apoptotic MEFs on E0771 
cells 
 
4.3.1 Cell viability  
 
An MTT assay was used to assess the cell viability of E0771 cells after a 24-hour treatment 
period with apoptosis and senescence CM collected from MEFs with or without DXR. Cell 
viability was significantly reduced in CM groups treated with DXR (p<0.05), however, 
senescence CM treated with DXR had a significant increase in cell viability when compared 
to the control and apoptosis CM treated with DXR (Figure 3.12).  
Similarly, Amornsupak et al found that when MDA-MB-231 breast cancer cells were pre-
treated with conditioned media from breast cancer associated fibroblasts, the cancer cell 
cultures showed less cell death after a DXR (5 µM) treatment period for 48 hours, when 
compared to cancer cells pre-treated with conditioned media from non-tumour associated 
fibroblasts (Amornsupak et al., 2014). These findings therefore support the ability of cancer 
cells to evade apoptotic cell death after DXR has been administered.  
To the best of our knowledge, apoptosis and senescence CM treatment in breast cancer is a 
novel study, but the expression of apoptotic and senescence markers can be compared with 
other studies, which have similar results.  
 
4.3.2 Markers of apoptosis following conditioned media treatment  
 
Cytotoxic agents, like DXR, induces apoptosis by activating death signalling pathways in target 
cells (Fisher, 1994). Western blot analyses were therefore used to determine whether E0771 
cells undergo apoptosis after the cells were treated with apoptosis and senescence CM, with 
or without DXR. As mentioned previously, DXR activates caspase activity, which in turn 
activates the execution of the apoptotic pathway.  
In 2016, Pilco-Ferreto and Calaf found that caspase-8 (the death receptor signalling kinase) 
protein expression is significantly upregulated in MDA-MB-231 cells after DXR treatment, 
however, based on our findings, no significant changes were found in the expression of 
caspase 8 after the DXR treatment period in all CM groups (p>0.05). Significant changes were 
observed in the decreased expression of caspase 8 in senescence CM treated with DXR 
relative to the control CM treated with DXR (p<0.05), which could indicate that less apoptosis 
occurred in senescence CM (Figure 3.13).  
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After the treatment period, no significant changes were observed in the expression of caspase 
9 (p>0.05) (Figure 3.14). Pilco-Ferreto and Calaf showed that caspase 9 was significantly 
increased in MDA-MB-231 cells after a 48-hour treatment period with various concentrations 
of DXR. Caspase 9 is an initiator caspase involved in the intrinsic apoptotic pathway and the 
results obtained during our study suggests that Caspase 9 has not been activated due to the 
lack of caspase 9 cleavage after the treatment period, which could therefore suggest that only 
the extrinsic apoptosis pathway was activated during the 24-hour treatment period.  
Caspase 3 is required for typical hallmarks of apoptosis like chromatin condensation and DNA 
fragmentation. In this study, caspase 3 expression was significantly decreased in senescence 
CM treated with DXR (p<0.05) however, no significant changes were observed in caspase 3 
expression after treatment with DXR (Figure 3.15). Contradicting to these results, it was found 
in other studies that caspase 3 expression is significantly decreased in MCF-7 cells after a 
DXR treatment period for 48 to 72 hours (Yang et al., 2001; Pilco-Ferreto & Calaf, 2016).  
PARP is a conserved nuclear protein that binds to DNA strand breaks. Organisms with a 
PARP deficiency display impaired base extension repair as well as genomic instability, which 
indicates that PARP functions to respond to severe DNA damage (Shall & de Murcia, 2001). 
DNA damage therefore increases PARP activity to allow cancer cells to repair DNA that has 
been damaged, to be able to continue growing. DXR is a powerful DNA-damaging agent, 
however, its direct effects on PARP activation has not fully been elucidated. PARP expression 
was significantly decreased in senescence CM as well as in senescence CM treated with DXR 
(p<0.05) (Figure 3.16). Munoz-Gamez et al indicated that PARP is rapidly activated in MDA-
MB-231 cells after 60 minutes of DXR treatment (Munoz-Gamez et al., 2005). Additionally, 
Wang et al showed that Adriamycin (chemotherapeutic agent) induced PARP activation in 
MCF-7 cells, but did not have any effects on cleaved PARP after 24 hours (Wang et al., 2014).  
The expression of most apoptosis markers was significantly decreased in senescence CM 
treated with DXR which is supported by the increase in cell viability in senescence CM treated 
with DXR, compared with both apoptosis and control CM. These findings therefore indicate 
that E0771 cells treated with senescence CM and DXR were able to evade apoptotic cell death 
and continue to grow, which supports the ability of senescent MEFs to secrete factors that 
promote treatment resistance.  
 
4.3.3 Markers of senescence following conditioned media treatment  
 
Western blot analyses were used to determine whether senescence was induced in E0771 
cells after the treatment period. MCM2 plays an important part in the cell cycle during DNA 
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replication and was therefore used as a proliferative marker to determine why the cancer cells 
have the ability to continue growing after DXR had been administered. The expression of 
MCM2 was significantly increased in senescence CM as well as senescence CM treated with 
DXR (p<0.05). (Figure 3.17). Similarly, Abe et al observed that once MCM2 translocation to 
the nucleus is inhibited, DXR-induced apoptosis is enhanced (Abe et al., 2015). Furthermore, 
Etemad-Moghadam et al stated that an increase in MCM2 gene expression is associated with 
a poor prognosis and an unfavourable response to DXR therapy (Etemad-Moghadam et al., 
2013). The increased expression of MCM2 in the senescence CM treatment group therefore 
indicates that the cancer cells were able to proliferate, which is also supported by the 
decreased expression of several apoptosis markers. However, markers of senescence (a non-
proliferative state) were also increased in the E0771 cells. The p16 protein was also assessed 
after the treatment period. p16 is a tumour suppressor protein which inhibits cyclin-D 
dependent protein kinases, by regulating the G1 phase to the S-phase during the cell cycle 
(Romagosa et al., 2011). The expression of p16 (Figure 3.19) and total RB (Figure 3.20) was 
increased in senescence CM with DXR (p<0.05), which indicates that these cells were in a 
senescent state and were not able to grow, however, this finding is contradicted by the 
increased expression of MCM2. The increased expression of RB (a tumour suppressor protein 
that prevents excessive cell growth) is supported by the study of Jackson and Pereira-Smith 
who observed that RB and its family members were enhanced in MCF-7 cells after a DXR 
treatment period and the authors also concluded that the expression of any RB family 
members is sufficient to induce cell cycle arrest (Jackson & Pereira-Smith, 2006). In 2011, 
Yang et al indicated that the upregulation of p16 promotes senescence in breast cancer cells 
(Yang et al., 2011).  
The p53 protein is a tumour suppressive protein that plays a role in both senescence and 
apoptosis, as mentioned previously. The expression of p53 was significantly increased in 
apoptosis CM treated with DXR (p<0.05) (Figure 3.18). Oncul and Recan observed that p53 
is activated in MCF-7 cells after low doses of DXR (800 nM) which led to cell cycle arrest in 
the G1 phase (Oncul & Recal, 2017). When comparing cell viability in CM-A-DXR and CM-C-
DXR (Figure 3.12), no changes were observed. The increase in p53 expression could 
therefore indicate that cell growth was arrested in CM-A-DXR and the cells were not able to 
grow.  
The expression of senescence markers therefore indicate that the breast cancer cells were 
able to proliferate even after DXR had been administered (MCM2), however, the expression 
of p16 and RB which maintain a senescent state in cells, was also increased, indicating that 
these cells were in a non-proliferative state. The contradicting data could be because the 
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amount of senescence induction in MEFs was only 56% where literature has suggested that 
it should be 80%. Furthermore, the treatment duration could also contribute to these findings.  
 
4.3.4 Markers of autophagy following conditioned media treatment  
Autophagy is a normal physiological process that maintains cellular homeostasis by digesting 
damaged cellular components in lysosomes (Rodriguez-Enriquez et al., 2004). Basal levels of 
autophagy are found in all cell types, but can also be induced by external stressors like 
chemotherapeutic drugs (Kondo & Kondo, 2006; Maiuri et al., 2007). Studies suggest that 
autophagy promotes resistance to cell death within cancer cells, however, the role of 
autophagy in cancer remains controversial because of its cytotoxic or cytoprotective effect 
(Huang et al., 2016). Cell viability was significantly decreased in the control conditioned media 
groups once Bafilomycin (a late stage autophagy inhibitor) was added (p<0.05) but was 
increased in apoptosis and senescence conditioned media (p<0.01 and p<0.05) (Figure 3.21). 
This could therefore suggest that autophagy had a cytoprotective role towards cancer cells in 
the control conditioned media and a cytotoxic role towards cancer cells in the apoptosis and 
senescence media, indicating that the autophagic process was contributing to cancer cell 
death and not promoting treatment resistance.  
During autophagy, LC3 in its cytosolic form (LC3 I) is conjugated to phosphatidylethanolamine 
to form LC3-phosphatidylethanolamine conjugate (LC3 II) and is therefore used to represent 
autophagic flux (Tanida et al., 2008). The western blot analyses of LC3 II indicated that it was 
significantly increased in conditioned media groups treated with Bafilomycin (p<0.05) which 
represents autophagosome accumulation, as expected with autophagy inhibition (Figure 
3.23). However, no significant changes in the expression of autophagic flux (defined as a 
measure of autophagic degradation activity) was observed (Loos et al., 2014). The 
immunocytochemistry results also show similar results, where LC3 II was increased in the CM 
groups treated with Bafilomycin but no changes in autophagic flux was observed (p>0.05) 
(Figure 3.26.1). Similar to these results, Guo et al found that LC3 levels were significantly 
increased in MCF-7 cells after a treatment period with Chloroquine and high dosages of DXR 
(Guo et al., 2016).  
p62 (or sequestosome 1) is an autophagy substrate that reports autophagy activity and has 
various roles in tumourigenesis and caspase activation (Liu et al., 2016). Studies also suggest 
that p62 is a selective cargo receptor that links ubiquitinated protein aggregates to autophagic 
machinery, through LC3 (Pankiv et al., 2007). Furthermore, although not significant, the 
expression of p62 was increased in CM-A-DXR-Baf when compared to CM-A-DXR indicating 
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that a slight increase in autophagic flux had occurred (p>0.05). However, Loos et al indicated 
that the expression of p62 in western blot analysis should be plotted over time to represent 
autophagic flux (Loos et al., 2014). No significant changes of p62 was observed in the 
senescence conditioned media groups (p<0.05). Similarly, Guo et al also indicated that p62 is 
significantly increased in MCF-7 cells treated with Bafilomycin and DXR when compared to 
control groups (Guo et al., 2016). The authors therefore suggested that breast cancer cells in 
the presence of DXR upregulate p62 expression for survival. No significant changes in the 
immunocytochemistry analysis of p62 were observed to represent changes in autophagic flux 
(p>0.05) (Figure 3.26.2). However, the results obtained for p62 from western blots and 
Immunocytochemistry differ and further assessment must be implemented. Several studies 
have demonstrated that weakly basic chemotherapeutic drugs, like DNA binding 
anthracyclines (DXR), can accumulate in lysosomes and is ultimately targeted to be degraded, 
which diminishes the ability of DXR to target the DNA of cancer cells. The sequestration of 
chemotherapeutics into lysosomes is therefore considered to be a mechanism of resistance 
in cancer cells (Hindenburg et al., 1989; Coley et al., 1993). As a result, the above mentioned 
could potentially explain why autophagy had a cytoprotective role towards cancer cells in the 
control conditioned media groups (Figure 3.21).  
 
4.3.5 Markers of proliferation following conditioned media treatment  
The expression of Akt and ERK was used to determine whether the E0771 cells were able to 
continue proliferating after the treatment period with conditioned media and DXR because the 
senescence conditioned media showed an increase in cell viability, when compared to the 
control and apoptosis groups (Figure 3.12). Lately, the role of Akt has received much interest 
in cancer research because it has the ability to suppress apoptosis. In 1998, Cardone et al 
indicated that Akt blocks and inhibits the functioning of caspase 9, which could provide the 
rationale why no caspase 9 cleavage was observed during our study (Figure 3.14) (Cardone 
et al., 1998). Similarly, to our results, Li et al observed that phosphorylated Akt was increased 
in MCF-7 cells one hour after exposing the cells to 1 µM of DXR, followed by a robust increase 
in phosphorylated Akt after 24 hours, with no significant changes in total Akt (Li et al., 2005) 
(Figure 3.24.2). PI3K activation of Akt promotes the translocation of inactive Akt from the 
cytosol to the plasma membrane, through subsequent Akt activation through phosphorylation 
at the Thr308 and Ser473 sites. Akt plays an important role in many intracellular signalling 
systems like cell growth, proliferation and protection from apoptosis (Downward, 2004). Akt-
mediated cellular functions are regulated by many hormones and growth factors, including 
EGF, IGF and VEGF. Overall, growth factors that promote Akt activation regulates the 
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transition of the cell cycle from the growth phase to the synthesis phase. Upstream effectors 
that activate Akt include PI3K and PTEN whereas downstream effectors mainly include 
mTOR. Carcinogenesis is highly dependent on external environmental stressors as well as 
genetic and epigenetic mutations to activate cellular oncogenes and at the same time inhibit 
tumour suppressor proteins. One of the hallmarks associated with an altered cellular 
phenotype is the overexpression/activation of Akt. Akt intracellular signalling maintains cellular 
biology which creates a steady equilibrium between tumour suppressor proteins and proto-
oncogenes, however, if the balance is disturbed, proto-oncogenes prevail and cause the 
enhanced activation of Akt-related factors to contribute to a malignant phenotype (Karar & 
Maity, 2011). As mentioned previously, the PI3K/Akt pathway is maintained at baseline 
activity. This is associated with an increased expression of p21 in the cellular nucleus which 
induces cell cycle arrest. During this period, malignant transformed cells take advantage of 
the temporary growth arrest to repair genomic DNA. In order to overcome this arrest, the Akt 
pathway is subsequently activated resulting in the nuclear rejection of p21 within the nucleus, 
to resume the proliferation program (Galluzi et al., 2012). 
During our study, the ratio of phosphorylated Ser473 Akt to total Akt was used as a proliferative 
marker to determine Akt activation. Phosphorylated Akt was significantly increased in CM-A, 
CM-A-DXR and CM-S (p<0.05) (Figure 3.24.1), which is supported by the significant decrease 
in total Akt expression in the above-mentioned groups (Figure 3.24.2). A significant increase 
in the ratio between pAkt/Total Akt was observed in CM-A, CM-A-DXR and CM-S (p<0.05) 
(Figure 3.24.3) which can be attributed to the significant increase in phosphorylated Akt, while 
total Akt levels remain unchanged. The increase in cell viability in CM-S-DXR (Figure 3.12) 
could therefore be attributed to the significant increase in Akt expression, which will allow the 
cancer cells to evade apoptotic cell death. Furthermore, total Akt expression was significantly 
increased in CM-C-DXR-Baf, CM-A-DXR-Baf and CM-S-DXR-Baf (Figure 3.24.1) with 
decreased expression for phosphorylated Akt (Figure 3.24.2) which leads us to believe that 
Akt activation had not been induced in these groups.  
ERK1/2 (also known as MAPK3 or MAPK1) is a serine/threonine kinase found in most 
mammalian tissue, where ERK2 levels are generally higher than ERK1 (Boulton et al., 1990). 
Dual threonine and tyrosine residue phosphorylation activates both ERK1 and ERK2, at 
Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2. Significant ERK 
activation requires phosphorylation at both sites (Ferrel & Bahtt, 1997). pERK2 was 
significantly increased in the CM-A-DXR group (p<0.001) indicating that significant ERK 
activation had occurred, however, p53 was also increased in this group (Figure 3.18) which 
could explain why apoptosis CM did not have a significant effect in cell viability changes 
(Figure 3.12). 
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ERK1/2 is a therefore a key signalling molecule which has been extensively investigated as a 
drug target for cancer therapy because the Ras/Raf/MEK/ERK pathway promotes proliferation 
and malignant transformation of cancer cells (Sebolt-Leobolt, J, 2000). In 2012, Taherian et 
al observed that the expression of phosphorylated ERK1/2 and total ERK1/2 was decreased 
in MDA-MB-231 cells after a DXR treatment period, but was increased in MCF-7 cells and is 
therefore highly cell line specific (Taherian et al., 2012). The increased expression of ERK in 
MCF-7 cells therefore opposes the apoptosis pathway, which is similar to our findings where 
a significant increase in ERK expression was observed in the senescence conditioned media 
group treated with DXR, indicating that these cells were able to evade apoptotic cell death and 
is also supported by the lack of caspase 9 activation in both cell lines (Figure 3.25.4).  
Not many studies have focused on the relationship between autophagy and ERK, but in 2013 
Martinez-Lopez observed that the cellular availability of autophagic structures determines the 
degree of ERK phosphorylation. The authors speculated that LC3-II-positive membranes and 
ATG5–ATG12-positive pre-autophagosomes could serve as cellular signalling platforms that 
would allow spatial coordination of the Raf-MEK-ERK cascade to facilitate ERK 
phosphorylation. Furthermore, the authors indicated that an increase in cell death in 
autophagy deficient cells may have occurred from decreased ERK activity (Martinez-Lopez et 
al., 2013). This phenomenon was also observed during our study where cell death was 
increased in control CM groups (Figure 3.21) supported by the decreased expression of ERK 
in control CM treated with Bafilomycin (Figure 3.25.4) as well as the increased expression of 
LC3 II in Bafilomycin treated cells (Figure 3.26.1). Therefore, manipulating ATG5–ATG12 and 
LC3-II availability could be a therapeutic strategy against multiple disorders that stem from 
altered ERK activity (Martinez-Lopez et al., 2013). 
The increased expression of Akt and ERK in the senescence conditioned media therefore 
suggests that these cells were able to proliferate even after DXR had been administered and 
potentially evades apoptotic cell death. However, contradictory to these above-mentioned 
results, the expression of senescence markers (like p16) was also increased (p<0.05), which 
indicates that these cells were in a senescent state and are therefore not able to grow. 
However, these results could have a different outcome when various treatment durations of 
DXR are administered or if a greater percentage of senescence was induced in the fibroblast 
population.   
Taken together, these results indicate that once senescence is induced in fibroblasts, tumour 
resistance is enhanced and the cancer cells have the ability to evade apoptosis. After 
investigating the effects of autophagy, the results suggest that autophagy contributes to 
cancer cell death in apoptosis and senescence conditioned media and does not contribute to 
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treatment resistance. Importantly, the effects of autophagy are cell line specific and should be 
optimized for each cancer cell line. Autophagy inhibitors will therefore not improve the clinical 
response to chemotherapy in E0771 breast cancer cells, but the effects of necrosis or 
necroptosis can further be investigated to determine why the cancer cells are able to evade 
cell death.  
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5. Conclusion  
__________________________________________________________________________________ 
 
Senescent cells actively communicate with neighbouring cells and the TME, through the 
secretion of molecules that constitute the SASP (cytokines, chemokines, and growth factors). 
Senescent fibroblasts secrete certain factors that could promote the proliferation of cancer 
cells. The aim of this study was to assess the effects of conditioned media harvested from 
senescent and apoptotic fibroblasts on breast cancer cells. The results support the idea that 
fibroblasts can secrete paracrine factors that affects breast cancer growth and therapeutic 
resistance and that these effects differ when senescence and apoptosis is induced in the 
fibroblasts. Conditioned media from fibroblasts decreased cellular death in E0771 breast 
cancer cells treated with DXR, however, autophagy contributed to cancer cell death and other 
mechanisms of resistance must be investigated. We have therefore clearly demonstrated that 
fibroblasts are influenced by DXR treatment to secrete factors which make cancer cells less 
susceptible to cell death induced by chemotherapy. Our results also indicated for the first time 
that even a 56% senescent fibroblast population was able to significantly increase cell viability 
in E0771 cells after DXR treatment.  
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6. Summary of key findings 
__________________________________________________________________________________ 
 
 
Figure 6.1: A summary of the key findings. Fibroblasts secrete growth factors and cytokines that 
affect cancer cell growth. Apoptosis and senescence was induced in a MEF population to generate 
conditioned media. Senescence CM allowed mouse breast cancer cells to evade apoptotic cell death 
even after DXR had been administered. Controversial to many studies, autophagy contributed to cancer 
cell death and not treatment resistance in apoptosis and senescence CM groups. The ability of E0771 
cells to evade apoptotic cell death is attributed to significant increase in Akt and ERK expression, which 
enhances proliferation and suppresses the apoptotic pathway.  
 
Figure 6.2: Akt and ERK contributes to cancer cell proliferation and DXR treatment resistance. 
Akt inhibits the expression of pro-apoptotic family members to inhibit programmed cell death by blocking 
apoptosis. The PI3K/Akt pathway can induce pro-survival signalling in both cancerous and non-
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cancerous cells and could therefore explain why cell viability was increased in senescence CM. 
Furthermore, the activation of ERK increases the expression of anti-apoptotic molecules, which will 
contribute to the ability of cancer cells to evade cell death and could also explain why no caspase 9 
activation was observed.  
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7. Limitations and future recommendations  
__________________________________________________________________________________ 
Ideally, the findings should be confirmed in an in vitro setting by increasing the sample size 
for better statistical power.  
The protocol for senescence induction should be optimized so that 80% of the cell population 
is senescent. These results can then be compared with the current findings to determine if 
there are any variations.  
The protocol for apoptosis induction in MEFs can further be optimized by altering treatment 
duration to determine whether there would be a different outcome. The expression of apoptotic 
markers could also be viewed at different time points to determine why there was minimal 
cleavage of certain caspase when DXR is known for its apoptosis induction. 
To further support the results, it would have been optimal to determine the expression of 
senescent and proliferation markers present in the E0771 cells after fibroblast CM treatment 
at various time points or after a longer treatment duration to determine why the contradictory 
results are present. 
Furthermore, western blot protocols could further be optimized specifically for E0771 cells. We 
were unable to obtain data for p21 in the E0771 cells.  
Identifying the presence of certain cytokines in the collected CM, such as IL-6, secreted from 
senescent fibroblasts will add value to obtained results by potentially elucidating the molecular 
mechanisms for the observed results.   
To determine why the cancer cells evade apoptotic cell death, the effects of necrosis should 
be investigated. 
Once these results are repeated and confirmed, it could suggest that by specifically targeting 
cancer cells and not stromal fibroblasts with chemotherapeutic agents, patients with breast 
cancer could have a better response to treatment.  
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9. Appendices  
 
Appendix A 
Senescence associated Beta-galactosidase staining solution   
Before use, all kit components must be thawed and mixed thoroughly until homogenous.  
Component Stock Solution 
Fixation buffer  
(20% Formaldehyde, 2% 
Gluteraldehyde, 70.4 mM 
Na2HPO4, 14.7 mM KH2PO4, 1.37 
M NaCl and 26.8 mM KCl) 
10x 
Reagent B 
Potassium Ferricyanide  
400 mM 
Reagent C 
Potassium Ferrocyanide  
400 mM  
X-gal solution (5-Bromo-4-
chloro-3-indolyl-ß-
galactopyranoside) 
40 mg/ml 
Staining Solution  10x 
Phosphate buffered saline 
(PBS) 
10x 
Distilled H2O   
 
 
 
Appendix B 
PBS: 0.1 M (2 litre)  
• 16g NaCl  
• 0.4g KCl 
• 2.88g Na₂HPO₄ 
• 0.48g KH₂PO₄ 
All reagents are dissolved in 1.8 litres of dH₂O (pH 7.4) and the final volume is adjusted to 2 
litres.  
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Appendix C 
Modified RIPA buffer (100ml)  
Add to 50ml of dH₂0:  
• 790mg Tris-base  
• 900mg NaCl 
Stir until dissolved, adjust pH to 7.4 
• Add 10ml of 10% NP-40 [1%] 
• 10ml of 10% Na-deoxycholate (1g in 10ml dH₂0) 
Stir solution until it turns clear.  
• Add 5ml of 100mM EDTA (5mM) (1.46g EDTA in 50ml dH₂0, pH 8.0) 
• Add 5ml of 100mM EGTA (5mM) (1.90g EGTA in 50 ml dH₂0, pH 8.0) 
• 1ml of 10% SDS 
Adjust to 100ml with dH₂0, aliquot into tubes and store in a 4⁰C fridge.  
 
Appendix D 
Bradford Assay: 
 
1. If needed, thaw protein samples on ice 
2. Thaw a 1mg/ml BSA stock solution 
3. Prepare BSA working solution (200μg/ml) by diluting 100μl BSA with 400μl dH2O (50ul 
BSA + 450ul dH20 if using 2mg/ml BSA stock). Vortex 
4. Prepare Bradford standards as follow (in duplicate): 
 
μg Protein 200μg/ml BSA dH2O Bradford Reagent 
0 (Blank) 0μl 100μl 900μl 
2 10μl 90μl 900μl 
4 20μl 80μl 900μl 
8 40μl 60μl 900μl 
12 60μl 40μl 900μl 
16 80μl 20μl 900μl 
20 100μl 0μl 900μl 
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5. Vortex protein samples 
6. For each Bradford sample, add 5μl of protein sample to 95μl dH20 and 900μl Bradford 
reagent. Prepare samples in duplicate. 
7. Vortex Bradford samples and standards 
8. Zero spectrophotometer with blank and set @ 595nm 
9. Read absorbencies 
10. Draw standard curve in Excel graph and plot values of sample to determine [protein 
sample] 
 
Sample Preparation (for western blot): 
1. Prepare a working solution of Laemmli’s sample buffer   
- 850µl Laemmli’s stock buffer solution + 150µl β-mercaptoethanol  
- Work in fume hood and Vortex thoroughly 
2. Prepare samples by adding the appropriate amount of protein sample to sample buffer 
(as determined with Bradford Assay) 
- In order to give equal amounts of protein for loading = 50μg 
- Work in fume hood 
- Vortex 
3. Store as ready-made samples 
OR 
Proceed with western blot 
4. Punch a hole in the lid of each sample and boil for 5min @ 95°C 
5. Mix by brief centrifugation (pulse) 
6. Samples now ready for loading 
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Appendix E 
Laemmli’s Sample Buffer (3x)  
• Dissolve 9.09g Tris in 100ml dH₂0 
• Add 6ml 10% SDS and stir (pH 6.8) 
• Make up to 100ml dH₂0 
• Weigh off 60g glycerol and add 99.9ml of above-mentioned solution  
• Add 26.4g SDS  
• Add 0.225g Bromophenol Blue and ensure to dissolve thoroughly  
• Adjust final volume to 225ml with dH₂0 
To prepare working solution, add 150ul β-mercaptoethanol to 850ul sample buffer (in 
fumehood) 
Final concentrations when adding sample buffer to sample in ratio of 1:2 
• 62.5mM Tris, pH 6.8 
• 4% SDS 
• 10% Glycerol 
• 0.03% Bromophenol Blue 
• 5% β-mercaptoethanol 
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Appendix F 
Western Blot  
 
Day 1 
1. Prepare BioRad Fast Cast Stain-Free gels according to instructions 
a. Gels can be made beforehand and stored in the fridge in wetted paper towels 
and sealed in cling wrap 
2. Thaw protein samples on ice 
a. Prepared in 2:1 ratio of protein sample + Laemli’s buffer 
3. Punch hole in lid of eppie, mix by vortexing briefly and boil for 5 min at 95°C 
4. Spin samples down with quick pulse 
5. Assemble the gasket 
a. Assemble the gels onto the gasket with the comb facing inside 
b. Fill the gasket with running buffer – check for leaks 
c. Carefully remove the combs and rinse out wells with P200 pipet (set to approx. 
100 ul) and yellow tip 
6. Load ladder (4 ul BLUeye) 
7. Load samples 
8. Place gasket into tank and fill with running buffer. Re-fill gasket if necessary 
9. Attach lid (black on black, red on red) and plug into power pack 
10. Run at 100 V for approx. 10 min (until sample has entered gel) 
11. Increase to 120-150 V and run until blue dye front reaches the bottom of the gel 
(approx. 1 hr) 
12. When finished, transfer immediately  
13. Activate stain-free properties of gel on ChemiDoc  
a. Gel activation protocol, 2.5 min 
14. Prepare for transfer (few min beforehand) 
a. Soak two pieces of blotting paper in transfer buffer for 2 min 
b. Activate piece of PVDF membrane in 100% methanol (10-15 sec) and then 
soak in transfer buffer for 2 min 
c. Size 7 cm x 8.4 cm – blotting paper and membrane should be same size, 
preferably gel also 
15. Assemble transfer sandwich (on TurboBlot tray) 
a. Place one piece of blotting paper 
b. Place membrane on top of blotting paper. Roll to remove bubbles 
c. Place gel on top of membrane 
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i. If transferring two gels in one tray, orientate gels with bottom towards 
centre 
d. Place second piece of blotting paper on top of gel. Carefully roll to remove 
bubbles 
e. Close with lid – be careful not to move lid while closing 
16. Transfer on TurboBlot according to desired settings 
a. Biorad defined HMW setting generally works fine 
17. After transfer, disassemble stack 
a. Blotting paper can be re-used 
b. Gel can be visualised to determine transfer efficiency if desired 
18. Label membrane and rinse in 100% methanol 
a. Labelling – only use soft pencil (black art pencil works well) and not markers or 
pens (causes smudges) 
b. Either label membrane while still on transfer stack or place membrane only on 
ethanol cleaned surface (white tray from Chemidoc works well) 
19. Air-dry membrane  
a. Becomes white 
b. Hold in fumehood for quicker drying 
20. Re-hydrate membrane in 100% methanol 
a. Until translucent, 10-15 sec 
21. Wash membrane in TBS-T for 5 min 
22. Image transfer on membrane on Chemidoc 
a. Stain-free blot setting 
b. If using for normalisation, make sure image is clean and not over-exposed 
23. Block membrane in 5% milk (prepared in TBS-T) for 1 hr with gentle shaking 
a. Or 5% BSA (prepared in TBS-T) for when probing for phosphorylated proteins 
24. Wash membrane 3x for 5 min in TBS-T 
25. Incubate membrane on primary antibody O/N at 4°C 
a. Prepared in 50 ml centrifuge tube 
b. Dilute antibody in TBS-T to desired concentration, normally 1:1000 
c. Attach to rotators in walk-in fridge 
i. Make sure tube/s are straight and rotor is balanced 
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Day 2 
1. Retrieve membranes 
a. Store primary antibody in fridge/freezer 
b. Mark on tube how many times primary antibody has been used 
2. Wash membrane 3x 5 min in TBS-T 
3. Incubate membrane on secondary antibody for 1 hr at RT 
a. Prepared in 50 ml centrifuge tube 
b. Dilute antibody in TBS-T to desired concentration, normally 1:10 000 
c. Place on roller in WB room 
4. Wash membrane 3x 5 min in TBS-T 
5. Develop 
a. Prepare minimum amount of ECL needed in Eppendorf tube in 1:1 ratio  
b. Place membrane on Chemidoc and check position 
c. Add ECL to the desired area and roll to ensure even spread. Roll away excess 
ECL 
d. Expose using desired settings 
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Appendix G 
Immunocytochemistry  
1. Seed cells onto sterile glass coverslips, in 6-well plates, and perform experiments as 
usual   
2. Remove coverslips from wells and place onto dry slides. By keeping the slide dry, it 
will ensure that the liquid stays only on the coverslip 
3. Gently wash twice with PBS (drop onto coverslip until covered) 
4. Fix cells for 3-5 min at RT  
5. Wash three times with PBS 
6. Block for 30-60 min at RT – use 200 μl per coverslip  
7. Remove blocking solution (do not wash) 
8. Add primary antibody and incubate O/N at 4°C – use 80-100 μl per coverslip. Can be 
prepared in blocking solution or in PBS. Secondary antibody controls should be 
incubated with PBS 
9. Wash three times with PBS 
10. Add secondary antibody and incubate for 1 hr at RT, protected from light – use 80-100 
μl per coverslip. Can be prepared in blocking solution or in PBS. 
11. Wash three times with PBS 
12. Counterstain nuclei with Hoechst (10 μg/ml, prepared in PBS) for 10 min 
13. Wash three times with PBS 
14. Carefully push the coverslip off slide and onto a paper towel (remember to keep it wet)  
15. Clean and dry the slide as needed and place a small drop of mounting media onto the 
slide  
16. Drain off excess PBS from the coverslip by holding a corner against a paper towel. 
Gently drop the coverslip onto the drop of mounting media with the cells facing 
downward to the slide 
17. Leave to dry for 30-60 min at RT 
18. Seal the slide with clear nail polish and leave to dry for another 30-60 min at RT 
19. Store at -20°C, protected from light, until ready to image.  
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Appendix H 
Image Processing  
 
1. Deconvolute image stack (Huygens Professional Software/ Olympus Cell^R Software).  
 
2. Make a maximum intensity projection of the deconvoluted z-stack (ImageJ).  
3. Split channels into respective signal subsets (ImageJ). 
4. Threshold images using adaptive Otsu thresholding (CellProfiler 3.1.5).   
 
 
Figure 1. Image deconvolution. A) Unprocessed raw z-stack (maximum intensity projection for sake 
of illustration). B) Deconvoluted z-stack (maximum intensity projection shown for sake of 
illustration).  
A B 
Figure 2. Image thresholding. A) Unthresholded image containing both Hoescht and GFP signal. B) 
Thresholded image of GFP signal only.  
A B 
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5.  Draw region of interest (ROI) around cells and save each ROI using ROI manager in 
ImageJ. Proceed with Particle Count (ImageJ). The total amount of particles will be 
displayed.   
 
 
 
 
 
Figure 3. Particle counts of ROIs. A) Region of interest drawn around cell. B) Particle count of ROI.  
A B 
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